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High-parameter flow cytometry is a crucial tool in immunology to assess kinetics and 
phenotypes of immune cell subsets in disease. With viral infections that have the 
potential to establish chronicity such as hepatitis B virus (HBV), productive immune 
functions must break down in order for a chronic infection to be established. On the other 
hand, with respiratory viral infections such as SARS-CoV-2, the causative agent of the 2019 
global pandemic, infections can range in symptoms from mild or asymptomatic to severe 
disease requiring hospitalization. In the case of SARS-CoV-2, prolonged severity of disease 
is believed to be in large part due to aberrant immune responses. In order to better 
understand what immunologic functions fail and/or become dysregulated, high-
parameter flow cytometry can be employed to interrogate exactly which immune cell 
subsets and/or functional pathways are altered leading to development of a chronic 
infection or severe disease. Reported here, we have developed two comprehensive flow 
cytometry panels to assess both global and antigen-specific adaptive immune responses 
in HBV infection to determine correlates of protection against developing a chronic 
infection. In addition, we employ two high-dimensional flow cytometry panels that 
simultaneously assess the immunologic profile and metabolic state of immune cell 
subsets in severe COVID-19 disease. Using this technique, we identified a metabolically 
distinct T cell subset unique to COVID-19 subjects compared to acute and chronic 
hepatitis C virus, severe influenza, and healthy controls. These T cells were found to be 
undergoing mitochondrial-induced apoptosis and their presence correlated with 
 iii 
lymphopenia in our subjects. In addition, we identified metabolically distinct myeloid-
derived suppressor cell populations that were uniquely upregulated in COVID-19 and 
correlated with disease severity. Overall, the use of high-parameter flow cytometry allows 
for detailed interrogation of immunologic profiles during disease and has led to the 
discovery of novel metabolic pathways that can be targeted for treatment of severe 
COVID-19 as well as helped identify circulating immune cell populations that correlate 
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Chapter 1: Introduction  
 
1.1 Overview of Innate and Adaptive Immune Responses to Viral 
Infections 
Productive immune responses are crucial to defending the body against infection. A 
coordinated effort between the first line, non-specific innate immune response and 
subsequent targeted adaptive immune response together provide the necessary tools to 
eliminate infection and produce memory against secondary exposure1. Below is 
described the main cell subsets involved in both the innate and adaptive immune 
response and broadly their roles in protecting against viral infection. 
 The innate immune system is responsible for the initial detection of a viral 
infection and for maintaining control of the infection until a specific adaptive immune 
response can be mounted. The main cell types involved in an innate immune response 
are monocytes, macrophages, dendritic cells (DCs), natural killer (NK) cells, and 
granulocytes such as neutrophils, basophils and eosinophils. Recognition of viruses 
largely occurs through pattern recognition receptors (PRRs) both on the surface of and 
within innate immune cells including monocytes/macrophages and DCs. PRRs include 
toll-like receptors (TLRs), NOD-like receptors (NLRs) and RIG-1 like receptors (RLRs) that 
together function to detect viral RNA, DNA, and structural or non-structural viral 
components to initiate an immune response2. Upon recognition of a virus through PRR 
detection, macrophages, monocytes and DCs will upregulate co-stimulatory molecules 
and release pro-inflammatory (IL-1b, IL-18, TNF, IL-6) or anti-viral (type I interferons – 
IFN⍺/β) cytokines and chemokines3.  
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Proinflammatory cytokines and chemokines attract additional innate immune 
cells to the site of infection. Neutrophils, often the first cells to arrive at the site of 
infection, function by phagocytosing foreign material, degranulating antimicrobial 
enzymes and releasing neutrophil extracellular traps (NETs) to trap microbes at the site 
of infection4. NK cells are an innate lymphoid cell type with cytotoxic potential. In viral 
infections they have the ability to recognize infected cells that have downregulated 
MHC Class I molecules and selectively kill those cells5. Plasmacytoid dendritic cells 
(pDCs) are a subset of DCs that are the principle producer of the antiviral cytokine IFN⍺, 
making them a crucial innate immune cell subset for viral control6,7. Macrophages have 
many functions and are often classified by their polarization as an M1 or M2 phenotype. 
M1 macrophages are more antiviral in nature and kill infecting pathogens or 
compromised cells/tissues, whereas M2 macrophages play a role in wound healing and 
tissue regeneration8. In the context of disease, and most well characterized in cancer, 
accumulation of an immunosuppressive immature innate myeloid cell type termed 
myeloid derived suppressor cells (MDSCs) can occur. The exact function and role of 
these cells is not well characterized but they have been found to accumulate in chronic 
infection and are thought to be a result of a feedback loop to limit persistent 
inflammatory signals during chronic infection9. 
After initial recognition of viral infection, the second role of the innate immune 
system is to direct antigen-specific development of the adaptive immune response. To 
do this, macrophages and DCs must present viral antigen to adaptive immune cells 
through their antigen presentation functions, lending to their classification as 
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professional antigen presenting cells (APCs)10.  Macrophages and DCs present antigenic 
peptides in the context of class I or II MHC molecules to CD8+ and CD4+ T cells, 
respectively10. In germinal centers of secondary lymphoid tissues, follicular dendritic 
cells (FDCs) present intact antigen to B cells11. Additional signals from APCs in the form 
of co-stimulatory molecules and cytokines are required to drive both T cell and B cell 
differentiation10. 
Once exposed to cognate antigen through APC presentation, adaptive immune 
cells differentiate into effector cells to drive antigen-specific responses to eliminate a 
viral infection and memory subsets to persist and rapidly respond in the case of re-
exposure to the same infection12. The main cells of the adaptive immune response are T 
cells and B cells. T cells represent the cellular arm of the adaptive immune response and 
consist of CD8+ T cells and CD4+ helper T cells. CD8+ T cells’ primary function is to lyse 
target cells. They maintain granules of lytic enzymes including perforin and granzyme 
and upon recognition of cognate antigen presented on MHC Class I from an infected 
cell, CD8+ T cells degranulate to lyse their target13. CD4+ T cells on the other hand mainly 
exert their function to support other lymphocytes through costimulation and cytokine 
production. CD4+ T cells promote antibody production from B cells, enhance effector 
CD8+ T cell responses, and maintain a CD8+ T cell memory pool14. CD4+ T cells 
differentiate into a number of helper subsets including T helper 1 (Th1), Th2, Th17, T 
follicular helper (TFH) and T regulatory (Treg) cells. Th1 cells mainly produce IFNy and 
have strong antiviral functions. Th2 cells in turn produce IL-4 and have negative 
immunopathological effects during viral infection14. Th17 cells produce IL-17, a pro-
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inflammatory cytokine. While an important cell type in bacterial/fungal infections, the 
role of Th17 cells in viral infections is still poorly understood15. TFH cells provide B cell 
help in the germinal center through expression of costimulatory molecule CD40L and 
production of IL-21, both of which are needed by B cells undergoing class-switching and 
affinity maturation16. Finally, Tregs serve a regulatory role to dampen immune 
responses after control of an infection to avoid unchecked inflammatory processes17. 
The humoral arm of the adaptive immune response consists of B cells and their 
functions. B cells are also considered professional APCs and can produce cytokines, but 
their main function is in antibody secretion. Antibodies are central molecules in fighting 
a viral infection, especially those with neutralizing functions. Neutralizing antibodies 
bind the surface of a virus in a way that blocks the virus’s ability to bind target cell 
receptors. The virus can no longer enter the cell and replicate, with the result that the 
infection can be cleared. Antibodies can also serve many additional non-neutralizing 
functions to aid in the clearance of infections such as complement activation, antibody-
dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis 
(ADCP) by macrophages/DCs18. The B cell subsets that secrete high levels of antibodies 
upon activation are plasmablasts and plasma cells. Plasmablasts are generated shortly 
after infection or vaccination and are often short-lived19. Plasma cells are further 
differentiated plasmablasts and can be maintained for long-term memory in addition to 
memory B cells20. Together, short-lived and long-lived plasmablasts, plasma cells and 
memory B cells serve multiple functions in order to defend against viral infection. 
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The coordinated effort of innate and adaptive immune cell subsets is crucial to 
defense against invading viral infections. If these functions break down, it can lead to 
establishment of a chronic infection. Alternatively, if a productive immune response is 
generated but cannot be dampened after viral control, it can lead to long term negative 
immune pathologic effects.  
 
1.2 Immunometabolism 
Immunometabolism is the recent field of study that examines alterations in metabolic 
pathways within immune cell subsets that affect immune cell function21. While many 
metabolic pathways have been examined in immune cells, four main pathways 
described below are glycolysis, tricarboxcilic acid (TCA) cycle, fatty acid oxidation and 
fatty acid synthesis. 
Glycolysis is the multi-enzyme metabolic pathway that converts glucose into 
pyruvate and ATP in the cytoplasm of cells22. The process is an inefficient mechanism for 
generating ATP compared to the TCA cycle but does not require oxygen. Pyruvate can 
then be reduced to lactate under hypoxic conditions or shuttled to the mitochondria as 
a precursor for the TCA cycle when oxygen is present22. A famous exception to this rule 
is the Warburg effect. First described in the 1920s, it was observed that cancer cells 
preferentially utilize glycolysis even in high oxygen conditions, termed “aerobic 
glycolysis”23. This effect first appeared counterproductive to a highly proliferating cancer 
cell’s need for energy, but new research suggests the benefit instead lies in facilitation 
of nutrient uptake that can be converted to biomass (nucleotides, amino acids, lipids)24. 
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Indeed, the rapidity by which an immune cell can increase glycolytic function as well as 
the utility of increasing biomass make glycolysis the metabolic pathway utilized by 
activated/effector macrophages25, DCs26, NK cells27, T cells28 and B cells29 during normal 
immune functioning. 
The TCA cycle on the other hand has been shown to be the main metabolic 
pathway utilized by quiescent cells in non-proliferative settings21,30. As a hub of cell 
metabolism, the TCA cycle utilizes multiple metabolic substrates including acetyl-CoA, 
the product of oxidized pyruvate generated during glycolysis, and in turn produces 
additional metabolites. In addition, the TCA cycle is tightly coupled with mitochondrial 
electron transport chain activity, which results in efficient production of ATP through 
oxidative phosphorylation (oxphos)31. Interestingly, in M1 macrophages, the TCA cycle is 
broken in two stages to aid in antimicrobial function. These breaks lead to citrate 
accumulation for additional fatty acid synthesis to increase membrane mass for antigen 
presentation, and succinate accumulation to aid induction of IL-1β through HIF-1⍺32,33. 
Another important metabolic pathway for immune cells is fatty acid oxidation or 
the reverse, fatty acid synthesis. Fatty acid oxidation is used to break down short to 
long-chain fatty acids within the mitochondria to produce intermediates acyl-CoA, 
NADH and FADH2 that are incorporated into the TCA cycle for generation of ATP through 
oxphos34. The pathway is used by non-inflammatory immune cell subsets that tend to 
have increased longevity such as Tregs, memory T cells and M2 macrophages21. Fatty 
acid oxidation helps regulate the balance between T cell effector and regulatory 
function by promoting Treg development and inhibiting polarization to T effector cells28. 
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At the same time, long-lived memory CD8+ T cells utilize fatty acid oxidation as a means 
to maintain energy needs but stay poised to respond quickly to antigen stimulation35. 
The reverse of this pathway, fatty acid synthesis, is an important metabolic process to 
generate lipids needed for cellular growth and proliferation21. Utilizing TCA cycle 
intermediates, mainly citrate, fatty acid synthesis occurs in the cytoplasm and results in 
production of de novo fatty acids. This process has been shown to promote a pro-
inflammatory immune cell state. For example, LPS and cytokine signaling can trigger 
fatty acid synthesis in macrophages36. 
Overall, it is clear that metabolism can directly affect and/or regulate immune 
cell function. Through broad immunometabolic approaches, increased details about the 
functional state of immune cell subsets can be determined in both health and disease.  
 
1.3 Hepatitis B Virus Clinical Characteristics and Immunology 
Despite the availability of treatment strategies and a preventative vaccine, hepatitis B 
virus (HBV) remains a significant global health burden. Over 2 billion people have been 
infected with HBV worldwide, and an estimated 257 million people are chronically 
infected. Chronic HBV infection (CHB) increases the risk to develop severe liver disease, 
cirrhosis, and hepatocellular carcinoma, resulting in over 887,000 deaths each year37,38. 
Interestingly, the rate of progression to chronic infection differs dramatically based on 
age of exposure to the virus. Most adults who acquire an acute HBV infection go on to 
control their infection with only a small subset (5-10%) progressing to CHB. In contrast, 
the majority of neonates (90-95%), especially those born to hepatitis B e antigen 
 8 
(HBeAg) positive mothers, progress to a chronic infection38,39. As many have 
hypothesized, this difference in infection outcome based primarily on age of exposure 
hints at a central role of functional and specific immune responses against HBV in 
controlling infection. 
Current therapeutic strategies to treat HBV have their limitations. The 
prophylactic HBV vaccine has been implemented in childhood vaccination strategies 
worldwide in over 180 countries since 1992. This has significantly decreased the 
incidence of newly acquired CHB around the world38,40. However, mother-to-child 
transmission still accounts for 40-50% of new HBV infections due to poor 
implementation of vaccine programs in HBV endemic regions41. In addition, prophylactic 
vaccination has no effect for the over 250 million people already chronically infected 
with HBV. For those with CHB, antiviral drugs approved for treatment fall into one of 
two categories: interferon-⍺ (IFN-⍺) or nucleos(t)ide reverse transcriptase inhibitors 
(NRTIs)42. These treatments are considered a partial cure in that they suppress viral 
replication and significantly decrease the risk of morbidity and death related to CHB but 
require lifelong treatment due to stable maintenance of HBV DNA in the infected liver. 
The main goal of current treatment strategies, therefore, is to achieve a functional cure, 
which is defined as sustained viral suppression off treatment. A functional cure would 
mimic natural resolution of an acute HBV infection and would likely induce robust HBV-
specific immune responses42,43.  
In order to determine whether robust HBV-specific immune responses are 
important as a potential functional cure strategy, the role of the adaptive immune 
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response in resolving acute HBV infections must be well understood. The following 
sections will provide an overview of what is known about global and antigen-specific T 
cell and B cell responses during HBV infection and the gaps in our understanding that 
need to be addressed before a functional cure for HBV can be achieved. 
 
1.3.1 HBV Structure and Life Cycle 
 
HBV is the prototype member of the Hepadnaviridae family of small hepatotropic DNA 
viruses. It contains a partially double-stranded, enveloped DNA genome 3.2 kb in size. 
The genome codes for four overlapping open reading frames (ORFs) that produce all 
seven of the HBV proteins44. The largest ORF encodes the viral polymerase (HBV pol). 
HBV pol has reverse transcriptase activity and is able to generate the full HBV genome 
from its genomic RNA intermediate. The second largest ORF encodes the three envelope 
proteins, small, medium and large that collectively make up the hepatitis B surface 
antigen (HBsAg). All three proteins share the same C terminal region that makes up the 
small HBsAg protein. Medium HBsAg contains the preceding preS1 sequence in addition 
to small HBsAg, while large HBsAg contains a unique preS2 region, preS1, and small 
HBsAg sequences. The third ORF encodes the structural nucleocapsid core protein 
(HBcAg) and the upstream precore protein or hepatitis B e antigen (HBeAg) which is not 
incorporated into virions but instead secreted from infected cells. Finally, the last ORF 
encodes the HBV x protein (HBx), a small regulatory protein essential for HBV 
replication45. 
The HBV life cycle initiates when HBV binds to its target cell the hepatocyte 
through an initial interaction with heparin sulfate proteoglycans (HSPGs) on the cell 
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surface46. The small HBsAg “a determinant region” is responsible for this interaction. 
Next, the virus binds its main hepatocyte-specific receptor human sodium taurocholate 
costransporting peptide (hNTCP) through interaction with a preS2 region on the large 
HBsAg47. HBV tropism to the liver is a direct result of the hNTCP receptor, which is 
exclusively expressed on human hepatocytes48. 
Upon receptor binding and entry, the virus enters the nucleus where the partial 
double strand is repaired to form episomal covalently closed circular DNA (cccDNA). 
cccDNA acts as a stable template for transcription of 5 RNA intermediates: pre-genomic 
RNA (pgRNA, 3.5 kb) which serves as the template for the HBV DNA genomic material, 
2.4 and 2.1 kb RNA (transcripts that become L-, M-, and S-HBsAg), 3.5 kb RNA 
(translated into HBcAg), and a 0.7 kb RNA (translated into HBx)49.  cccDNA’s stability in 
the nucleus of infected hepatocytes is the cause of HBV viral persistence44,50.  
In order to form new HBV virions, pgRNA is encapsulated within the 
nucleocapsid (HBcAg) in association with HBV pol. Once packaged, pgRNA is reverse-
transcribed by HBV pol to produce the partially double-stranded HBV viral DNA 
genome51. The reverse-transcription step will occasionally produce a minor DNA 
product, double-stranded linear DNA (dslDNA) which is also secreted as a virion and 
represents 10% of plasma HBV DNA52. dslDNA is able to stably integrate into the host 
genome and is a secondary source of HBsAg production53. Finally, the viral particle is 
enveloped in association with HBsAg, and although still poorly understood, is thought to 
exit the hepatocyte through a pathway involving the endosomal sorting complex 
required for transport (ESCRT) pathway and multivesicular body (MVB) formation54. 
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Ultimately however, low amounts of virus are produced from infected cells; an 
estimated 1-10 virions per day55. 
A unique feature of HBV is its ability to over-produce HBsAg with release of 
subviral particles (SVPs). SVPs are spherical or filamentous lipid particles lacking HBV 
genomic material and HBcAg, but containing small HBsAg, and to a lesser degree 
medium and large HBsAg. SVPs are produced in 10,000 fold excess to fully intact 
virions56. This leads to high levels of circulating HBsAg that is thought to contribute to 
HBV immune tolerance and exhaustion. Although a relatively small virus, HBV both 
stably maintains its cccDNA genome in the nucleus and uniquely overproduces SVPs, 
together making it a difficult virus to control and treat.  
 
 
1.3.2 HBV Serology and Clinical Phases of Infection 
 
In the course of a natural HBV infection, serological markers are used clinically to classify 
patients in multiple phases of infection. Upon acute infection with HBV, the first 
detectable markers are the viral products HBV DNA followed by HBsAg and HBeAg in 
serum50. HBeAg, the soluble pre-core protein, can be cleared early during an acute 
infection, but HBV DNA and HBsAg persist throughout the course of clinical symptoms. 
The first antibody to appear clinically is against HBcAg (anti-HBc) followed soon after by 
anti-HBeAg (anti-HBe). Development of anti-HBe is observable after HBeAg clearance 
and is a favorable serologic marker during acute infection. Interestingly, anti-HBc 
antibodies are not protective, likely due to the ability of the core protein to cross-link B 
cell receptors (BCRs) and lead to T cell-independent B cell activation and production of 
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antibody57. The final serological marker to appear is anti-HBsAg (anti-HBs), although 
development of anti-HBs occurs only in patients who control their acute infection. 
Therefore, detection of anti-HBs is considered the clinical sign of resolution of infection. 
In HBV unexposed individuals, presence of anti-HBs indicates a protective vaccination 
status. In contrast, transition from an acute infection to CHB is defined by the presence 
of circulating HBsAg for greater than 6 months without development of anti-HBs58. Due 
to this pattern of seroconversion, anti-HBc is used to distinguish individuals who have 
been exposed to an acute HBV infection, whereas anti-HBs determines positive 
protection status.  
CHB can be further characterized into four sequential phases with distinct 
serological profiles59,60. The first phase is immune tolerance (IT), where patients are 
HBeAg+, anti-HBe- and have high HBV DNA but normal alanine transaminase (ALT), 
which is an enzyme produced by hepatocytes. Elevations in ALT suggest hepatocyte 
destruction. During the immune clearance or immune active phase (IA), HBeAg remains 
positive and anti-HBe does not develop, while HBV DNA levels are lower than in the IT 
phase and ALT spikes are observed. Transition to the immune control phase (IC) occurs 
with a loss of HBeAg and development of anti-HBe, further decrease in HBV DNA and 
normalization of ALT. Finally, the immune escape or HBeAg negative hepatitis phase 
(ENEG) maintains HBeAg-, anti-HBe+ seroconversion with elevated HBV DNA levels 
compared to the IC phase and occasional ALT spikes. The complex nature of CHB natural 
history underlies the fact that chronic infection is not a static state, and in order to 
 13 




1.3.3 T cell Responses in HBV Infection 
 
It is well established that T cells play an important role in the control of acute HBV 
infection, with CD4+ and CD8+ T cells exhibiting differing but complementary kinetics 
and functions. Early chimpanzee studies demonstrated that CD8+ T cells are the main 
effector cells in the control of acute HBV. With depletion of CD8+ but not CD4+ T cells 
during the peak of acute HBV infection, the duration of peak infection was significantly 
prolonged61. In addition, only upon the reappearance of CD8+  T cells was decrease in 
HBV DNA observed in the liver. Finally, full clearance of HBV DNA occurred without 
appearance of anti-HBs and only upon full restoration of CD8+ T cell frequencies, 
demonstrating a central role of CD8+ T cells in viral control. 
Interestingly, the method by which CD8+ T cells exert their effector function 
against HBV relies heavily on their non-cytolytic ability to produce cytokines61,62. In a 
transgenic mouse model, CD8+ production of IFNy and TNF was shown to inactivate 
intracellular HBV replication without hepatocyte lysis. As a vital organ for life, cytotoxic 
destruction of all infected hepatocytes during HBV infection would lead to unsustainable 
loss of liver function and this is likely the reason for a prominent role of non-cytolytic 
cytokine production in productive control of the virus. A follow up study performed in 
chimpanzees supported the transgenic mouse findings and showed that 90% of HBV 
DNA was eliminated from the liver through non-cytolytic functions early in the acute 
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HBV infection course (weeks 8-12)63. Only later were the presence of T cells detected in 
the liver (weeks 16-18) and their migration correlated with increased liver damage and 
serum ALT levels. The T cell dynamics of early non-cytolytic viral control followed by 
cytolytic activity and liver damage was also confirmed in a cohort of acutely infected 
humans64. 
 Further T cell depletion studies in chimpanzees revealed that CD4+ T cell priming 
of CD8 effector function is critical to maintaining a self-limited acute infection65. When 
CD4+ T cells were depleted prior to inoculation with an HBV dose that is typically cleared 
from a healthy animal, a chronic infection was established and no HBV-specific 
intrahepatic CD8+ T cell responses were detectable. In contrast, if CD4+ T cells were 
depleted after the onset of peak infection (6 weeks after inoculation), the animals were 
able to control their infection as expected. Overall, these data show the important 
kinetics of productive CD4+ priming of CD8+ T cells in the control of an acute HBV 
infection, as well as the unique non-cytolytic function of CD8+ T cells. 
 HBV-specific T cell responses are responsible for the HBV control dynamics 
described above, and it is believed that breakdown of these responses is largely 
responsible for progression to CHB. Profiling of HBV-specific T cells has revealed that 
their presence in both acute HBV infection and CHB occurs at low frequencies. For CD8+ 
T cells, only 0.01% to 2% of total circulating CD8s are HBV-specific, depending on 
infection status47. Specificity against HBsAg, nucleocapsid (HBcAg and HBeAg), HBx and 
polymerase have all been observed66–69.  
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Identification of HBV-specific T cells has mainly been performed by one of two 
methods. Direct ex vivo characterization using multimer staining has allowed for the 
identification of multiple dominant epitopes, mainly HLA-A2 restricted, in HBsAg (env 
183-191 and env 335-343), HBcAg (core 18-27) and HBV polymerase (pol 455-463 and 
pol 575-583)70. Although this method has the advantage of identification through TCR 
specificity alone, it suffers from the limitations of necessitating HLA typing of subjects 
and narrowing the scope of analysis to only a few specific epitopes from individual 
antigens. An alternative method used to identify HBV-specific T cells is in vitro peptide 
pool stimulation. Peptide pool stimulation followed by ELISpot or intracellular cytokine 
staining (ICS) allows for identification of HBV-specific T cells based on their activation 
and/or production of cytokines. This method is limited in that identification occurs as a 
functional readout rather than TCR specificity but has the benefit of allowing for 
assessment of entire HBV antigens and determining functionality simultaneously.  
 Both methods described have been utilized to assess HBV-specific T cell 
responses in acute and chronic HBV infection. During acute infection, a strong and 
multi-specific T cell response has been observed against HBcAg, HBsAg and HBV 
polymerase64,68,71,72. Frequencies of HBcAg-specific T cells are often detected at highest 
levels, followed by HBV pol-specific and finally HBsAg-specific cells71. In contrast, HBV-
specific T cell responses in CHB are infrequent and typically found mainly against HBcAg 
and HBV polymerase69,73. The limited detection of HBsAg-specific T cells in CHB is 
thought to be a result of T cell deletion, as their frequencies correspond strongly with 
amount of circulating HBsAg70,74. Further role of circulating HBsAg in limiting HBV-
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specific T cell responses was shown in a study stratifying CHB patients by HBsAg levels. 
Investigators observed greater HBV-specific CD4+ T cell responses (as shown by IFNy, 
TNF and IL-2 production) upon HBcAg and HBsAg peptide pool stimulation in HBsAglo 
individuals (<500 IU/mL)75. In contrast to this finding, another study showed that instead 
duration of HBsAg exposure, rather than quantity of circulating HBsAg, had a greater 
effect on HBV-specific T cells, specifically leading to deletion of HBsAg-specific cells76.  
Typically, functional readouts show that peripheral blood mononuclear cells 
(PBMCs) from CHB patients lack the ability to produce cytokines and proliferate in 
response to peptide pool stimulation with HBV antigens, whereas PBMCs from acute 
individuals can73. Interestingly, one study analyzed frequency and function of HBV-
specific T cells in CHB after long-term effective therapy with nucleos(t)ide analogues 
(NUC) and found that NUC treated HBsAg- individuals were able to respond to peptide 
pool stimulation after in vitro culture, with the highest frequency of cells producing IFNy 
followed by TNF then IL-269. This finding suggests that functional impairment of T cell 
responses observed in CHB may not be a permanent state. 
 It is widely believed that the lack of HBV-specific T cell response in CHB is a 
result of persistent exposure to a high level of antigen leading to T cell dysfunction 
and/or exhaustion. To address this hypothesis, multiple studies have assessed the 
phenotypic profiles of HBV-specific T cell responses with a focus on inhibitory and/or 
exhaustion marker expression. It has been observed that HBV-specific CD8+ T cells have 
high frequencies of PD-1+ cells in acute and CHB, but these frequencies decline upon 
control of an acute infection70,73. Interestingly, HBV-specific CD8+ T cells demonstrated 
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co-expression of PD-1 with CD127, which is believed to represent a phenotype of semi-
productive memory, and only upon subsequent downregulation of CD127 do these cells 
become severely exhausted73,77. It was observed that the majority of HBcAg-specific and 
HBV polymerase-specific CD8+ T cells in CHB patients with low viral loads demonstrate 
this memory-like CD127+PD-1+ phenotype, further characterized by expression of the 
transcription factor TCF1 that controls cell proliferative capacity74. However, HBV 
polymerase-specific cells examined in this study had a subset of cells with the PD-
1+CD127- terminally exhausted phenotype, accompanied by higher KLRG1 expression, 
further supporting that these cells are more terminally exhausted and highlighting the 
heterogenous nature of HBV-specific T cell exhaustion phenotypes based on their 
targeted antigens78. In support of these findings, a recent high-parameter analysis of 
HBV-specific CD8+ T cell phenotypes and functions in CHB patients was performed using 
multiplexed direct ex vivo tetramer staining79. Results showed that HBV-specific T cell 
phenotypes are extremely heterogenous, and that accumulation of inhibitory receptors 
did not directly correlate with dysfunction. Rather than identifying terminally exhausted 
phenotypes, the authors described their observations as a “functional adaption.” This 
concept has also been proposed for T cells in cancer, whereby T cells adjust their 
functional capacity to the lesser needs of an established chronic infection or cancerous 
state80.  
Additional exhaustion markers besides PD-1 have been shown to be upregulated 
on CD8+ HBV-specific T cells in CHB including CTLA-4, LAG3, TIM-3, 2B4 and CD160. 
Targeting these molecules via inhibition in vitro can partially restore HBV-specific CD8+ T 
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cell function81–84. To date, a handful of clinical trials have also been undertaken to assess 
the efficacy of immune checkpoint blockade for the treatment of CHB. One study was 
aimed to assess efficacy of PD-1 checkpoint blockade on hepatocellular carcinoma85. 
While treatment was well tolerated and a log decline in HBsAg was observed in 6% of 
CHB patients, T cell responses were not interrogated. Another phase 1b study examined 
PD-1 blockade in a group of HBeAg-, virally suppressed CHB patients86. One of 14 
patients experienced a functional cure, with most others demonstrating modest 
decrease in HBsAg over time (up to 0.5 IU/mL after 24 weeks post treatment). HBcAg- 
and HBsAg-specific T cell frequencies in this study did not increase after anti-PD-1 
treatment, and maximal T cell responses as shown by fluorospot occurred in the patient 
with functional cure. 
 In summary, HBV-specific T cells are crucial to the control of HBV infections. 
However, the dynamics of their functionality is extremely complex. Restoration of HBV-
specific T cell capacity in CHB for the goal of establishing a functional cure will likely 
necessitate previously attempted strategies of checkpoint inhibitor blockade against 
upregulated exhaustion markers, but clearly, additional modulation is needed. If in fact 
these HBV-specific cells have entered a “functionally adapted” state, perhaps more than 
just immunomodulation will be needed. Although not directly assessed in any studies, if 
HBV-specific T cells have undergone epigenetic modifications to establish a “functionally 
adapted” state, perhaps drugs targeting epigenetic alterations would be beneficial. In 
addition, HBsAg-specific T cell frequencies are extremely low in CHB, and strategies to 
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generate new HBsAg-specific T cells will also need to be considered, in parallel to 
methods to eliminate circulating HBsAg. 
 
1.3.4 B cell Responses in HBV Infection 
To date, study of the humoral response during HBV infection has been largely neglected 
despite the understanding that B cells must play an important role in the control of 
acute HBV. In the course of a natural HBV infection, HBV-specific B cells are activated 
upon antigen exposure to produce antibodies that target multiple HBV proteins. 
Antibodies produced against HBcAg, HBeAg, HBx, HBV pol and all three HBsAg (L-, M-, S-
) proteins have been observed47,87. While only a small subset of these antibodies, mainly 
those targeting the pre-S1 domain of large HBsAg and the a-determinant region of small 
HBsAg, have been shown to be neutralizing (reviewed in 87), the timing of 
seroconversion against different antigens helps to determine each clinical phase of HBV 
infection (see 1.3.1 HBV serology and clinical phases of infection). Importantly, 
induction of anti-HBs is considered the clinical indication of recovery from an acute HBV 
infection and demonstrates the role antibodies against HBsAg play in controlling 
infection. In addition, anti-HBs serves a protective function against acquisition of HBV, 
highlighted by HBIG administration to limit maternofetal transmission or reinfection 
after liver transplantation, and through successful prophylactic induction of anti-HBs as 
the protective mechanism of the HBV vaccine40,50,88,89.  
Although B cell mediated antibody production is clearly important for control 
and prevention of HBV, additional B cell functions also play a crucial role. This fact is 
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highlighted in studies of hematologic malignancies using CD20+ depleting rituximab that 
showed a 5-20% risk of HBV reactivation in previously recovered patients90–92. 
Plasmablasts and plasma cells, the most robust producers of antibodies, downregulate 
CD20 and are not depleted upon rituximab treatment indicating additional B cell 
functions such as antigen presentation and cytokine production are important for long-
term HBV control93. 
Initial examinations of B cells in HBV focused on global phenotypes and 
functions. In CHB, B cells demonstrate increased activation profiles with reduced 
proliferative capacity94,95. Activation signatures determined by CD69+ and/or CD71+ B 
cells occurred in both naïve and memory B cell subsets. When categorized by CHB 
disease phase, the majority of polyclonal B cell activation was observed in the immune 
active (IA) phase95. Multiple groups have also described increased frequencies of 
circulating IL-10 producing regulatory B (B reg) cells in CHB96,97. Presence of these cells 
was shown to downregulate CD4+ T helper functions in vitro and suggests B regs serve a 
pathogenic role in suppressing HBV-specific immunity in CHB. Overall, these data 
describe a hyperactive yet dysfunctional global B cell state with concomitant increase of 
B reg activity, indicating a high degree of dysregulation in the global B cell compartment 
during CHB. 
The phenotype and function of HBV-specific B cells has only recently begun to be 
examined. Two seminal studies reported the ex vivo detection of HBsAg-specific B cells 
in CHB, ending a decades-long debate about whether these cells were in fact present in 
CHB98,99. The lack of detection of anti-HBs in CHB patients was thought to be a result 
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either of very little anti-HBs production (through the deletion of HBsAg-specific B cells), 
or that cells were present and producing anti-HBs, but quantities made were insufficient 
to overcome excess circulating HBsAg. In the latter case, all anti-HBs would be bound up 
by HBsAg to form rapidly cleared immune complexes100–102. Although immune 
complexes of HBsAg bound to anti-HBs have been observed in CHB103 (indicating some 
degree of anti-HBs production), the newest data suggest HBsAg-specific B cells are 
present but have decreased functionality.  
HBsAg-specific B cells were detectable in both acute HBV infection and CHB, 
however, they were present at very low frequencies in both the periphery and the liver 
(0.01%-0.4% of CD19+ B cells)98,99. It was also shown that HBsAg-specific cells, when 
sorted and stimulated in vitro could not differentiate into antibody producing plasma 
cells like healthy vaccinated controls. This functional impairment occurred in HBsAg-
specific B cells from both CHB and acute HBV patients who were HBsAg+, but in the 
same patients at the time of seroconversion (HBsAg-, anti-HBs+), functionality was 
restored98. These observations suggest that HBsAg-specific B cell function is negatively 
affected by circulating HBsAg regardless of HBV infection outcome.  
In further support of dysregulated HBsAg-specific B cells is the finding that these 
cells were enriched for atypical memory B cells (AtMs). AtM B cells, identified by their 
downregulation of surface markers CD21 and CD27, have been observed at increased 
frequencies in a number of chronic infections such as Plasmodium falciparum (malaria), 
Mycobacterium tuberculosis (M. tb), human immunodeficiency virus (HIV), hepatitis C 
virus (HCV), and HBV104. These cells typically represent 3-5% of peripheral B cells in 
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healthy individuals but can expand up to roughly 50% of circulating B cells during 
chronic infection. AtM B cells express genes not characteristic for memory B cells such 
as the integrin CD11c and transcription factor Tbet, as well as many known or suspected 
inhibitory receptors including CD32b, CD72, CD22, PD-1, BLTA, CD85 and Fc like 
receptors FcRL4 and FcRL5. Overall, these cells appear refractory to expansion and 
antibody/cytokine production in response to BCR stimulation and are suspected to 
represent a dysfunctional memory B cell phenotype during chronic infection104.  
In contrast to the findings above, HBcAg-specific cells are present in CHB subjects 
at increased frequencies and are more functional105,106. These cells were shown to be 
present at higher frequencies than HBsAg-specific B cells in CHB subjects and they could 
differentiate into antibody secreting plasma cells upon in vitro stimulation105. In 
addition, they were not enriched for an AtM B cell phenotype. Interestingly, while 
HBsAg-specific B cells expressed mainly IgM+ BCRs, HBcAg-specific cells were largely 
IgG+, suggesting HBsAg-specific B cells may not readily enter the germinal center to 
undergo class-switching and affinity maturation for production of high affinity HBV-
specific B cell clones. At the transcript level, HBcAg-specific B cells revealed a 
differentially expressed gene program compared with HBsAg-specific B cells. HBc-
specific cells had increased expression of genes associated with class-switch 
recombination (CD99, IL6R and CXCR3), while HBsAg-specific B cells had increased 
expression of CD31, a molecule shown to play a role in maintaining B cell tolerance, as 
well as NFATC1, important for B cell homeostasis/apoptosis and finally, higher levels of 
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TNFRSF13B (TACI) which indicate their similarity to marginal zone-like B cells105. To date, 
HBV-specific B cell responses have only been assessed against HBsAg and HBcAg.  
Taken together, these data are consistent with serological observations in HBV 
infection. Namely that anti-HBc is observed early and throughout infection and HBcAg-
specific B cells are detectable at higher frequencies and appear functional. In contrast, 
anti-HBs does not appear in CHB subjects and HBsAg-specific B cells, while detectable, 
were present at low frequencies, could not differentiate, did not appear to have entered 
the germinal center as consistently (mainly express IgM) and had increased frequencies 
of AtM B cells.  
The data also highlight the importance of antigen-specific consideration when 
designing a functional cure. In order to generate a successful cure strategy, restoring 
functionality of HBsAg-specific B cells is crucial, while targeting HBcAg-specific cells may 
not be necessary. To this end, Salimzadeh et al. found that in vitro treatment with anti-
PD-1 antibodies was able to partially restore HBsAg-specific B cell functionality in CHB 
subjects98. Although anti-PD-1 therapy could serve a role in reversing the apparent 
dysfunctional B cell compartment in CHB, it is likely not a silver bullet approach. An 
effective functional cure will most likely involve a multi-pronged strategy including an 
antigen-specific approach to eliminate circulating HBsAg, a driving factor in mediating 





1.3.5 Consequences of HBV and HIV Coinfection 
Coinfection with HBV and HIV is common, mainly due to similar routes of transmission 
and geographic overlap of high burden regions108. 40 million people are infected with 
HIV worldwide, and of that number, an estimated 10% are coinfected with HBV109. In 
regions with low endemicity, HBV and HIV are acquired in adulthood usually through 
sexual or percutaneous transmission, and the prevalence of HBV and HIV coinfections is 
5%-7% of HIV infected individuals. However, that prevalence is much higher among men 
who have sex with men (MSM), between 9%-17%. In areas with high HBV endemicity, 
HBV transmission occurs perinatally, leading to established HBV infection in early 
childhood that precedes HIV infection sometimes by decades. Prevalence of HIV/HBV 
coinfection in these regions is much higher, on average between 10%-20%108,109.  
 Coinfection with HIV negatively affects the natural history of HBV infection. HIV 
infected individuals are 6 times more likely to develop CHB compared to HIV uninfected 
persons110,111. In addition, HIV infection decreases the rate of HBeAg clearance and 
increases HBV replication as seen by circulating DNA levels112,113. Even after acquiring 
protective anti-HBs, indicative of a controlled HBV infection, HIV-infected individuals are 
at risk of losing anti-HBs and reactivating their HBV infection with reappearance of 
HBsAg and HBV DNA (known as reverse seroconversion)114,115. Finally, HIV infection 
accelerates the progression of HBV-related liver disease. Cirrhosis is more common and 
liver-related mortality is 17 times more likely in coinfection116. Interestingly, coinfection 
with CHB in HIV infected persons increases the risk of hepatotoxicity from antiretroviral 
therapy (ART) drugs 3-5 fold117. Decisions on treatment strategies for HIV/HBV 
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coinfected patients is also complicated by the fact that multiple nucleoside analogs are 
active against both HIV and HBV and careful consideration to avoid emergence of drug-
resistant variants must be made. 
In summary, coinfection of HIV and HBV can lead to accelerated progression of CHB 
and liver disease, reactivation in HBV controlled individuals, and overall increased 
mortality. However, the mechanisms underlying these observations are still poorly 
understood. Studies that assess the immunologic effects of coinfection may identify 
novel targets or pathways to reduce mortality and improve outcomes in coinfected 
patients. 
 
1.4 SARS-CoV-2 Background and Immunology 
 
SARS-CoV-2 is a coronavirus responsible for the coronavirus disease 2019 (COVID-19) 
pandemic, to date with over 164 million cases worldwide118. COVID-19 is characterized 
by a range of disease severity, from asymptomatic/mild infection to severe disease 
requiring hospitalization119. Those patients who develop severe disease often require 
supplemental oxygen and/or ventilation and present with pneumonia or acute 
respiratory distress syndrome (ARDS), resulting in over 3.4 million deaths worldwide118. 
At this time, it is unclear why some patients readily resolve infection while others 
develop severe symptoms. Specifically, it remains to be determined if severe disease is 
associated with a failure to generate protective immunity against the virus allowing for 
prolonged viral replication, overly robust dysfunctional immune responses, or a 
combination of both.  
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 SARS-CoV-2 is the third highly pathogenic coronavirus (CoV) to demonstrate a 
zoonotic transmission to humans within the past 20 years120. Preceded by the SARS 
outbreak in 2003 and MERS outbreak in 2012, SARS-CoV-2 shares many features with 
other CoVs including the unique structural Spike protein, giving the virus the 
appearance of wearing a crown and to which its name can be attributed. SARS-CoV-2 is 
an enveloped positive-sense single-stranded RNA virus made up of four structural 
proteins and multiple accessory proteins121.  The main structural protein responsible for 
viral entry is Spike, which becomes activated by its interaction with the transmembrane 
serine protease TMPRSS2 and binds its primary receptor angiotensin-converting enzyme 
2 (ACE2) in order to infect bronchial epithelial cells, pneumocytes and upper respiratory 
tract cells122,123. 
To date, severe COVID-19 has been associated with multiple changes in peripheral 
immune profiles, including lymphopenia and increased pro-inflammatory cytokines124. 
Recent studies have broadly assessed immune profiles in COVID-19, revealing 
alterations in both the lymphocyte and myeloid compartments. Preferential loss of CD8+ 
T cells, increased plasmablasts, neutrophil expansion, decreased plasmacytoid dendritic 
cells (pDCs), and differential T cell activation have been observed125–128.  Although 
notable, the overall phenotypic characteristics of peripheral cell types shows extreme 
heterogeneity within severe COVID-19 infections. In addition, these observations are 
indicative of generalized inflammation and thus fail to distinguish specific host 
deficiencies in SARS-CoV-2 infection versus other viral infections or inflammatory states. 
Further studies that assess specific SARS-CoV-2 correlates of disease severity are 
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necessary in order to identify both biomarkers associated with severe disease and novel 
treatment strategies to mitigate severe pathologies. 
 
1.5 Flow Cytometry High-Dimensional Panel Design  
Recent technological advances in the field of flow cytometry have allowed for the ability 
to assess increasingly more immunologic information at the single-cell level. In addition 
to conventional flow cytometry techniques, cytometry by time of flight (CyTOF) and 
spectral flow cytometry are becoming more commonplace129,130. Although this work 
focuses on conventional flow applications, panel design concepts can be applied to 
these newer techniques as well. High-dimensional panel design is an ideal strategy for 
immunophenotyping and immune monitoring studies applied to research areas 
including infectious disease. Through optimization of comprehensive panels, extensive 
information can be garnered on a single-cell level from studies with often limited 
subjects or cell numbers.  
 The first step in designing a high-dimensional panel is to determine the antigenic 
markers of interest131. Markers can then be categorized by level of importance in the 
panel. Discrete lineage markers such as CD3, CD4 and CD8 for T cells are given highest 
priority. These markers are “on/off” and as such will have reliable detection by many 
antibody clone/fluorophore combinations. Secondary priority is given to markers with 
well characterized expression patterns that are on a continuum, for example, CD27, 
CD28, and CD45RA on T cells. Lowest priority is then assigned to markers expressed at 
low levels or that are uncharacterized, such as activation (CD154, CD69) or exhaustion 
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markers (PD-1, CTLA-4, TIM-3). Often these markers are phenotypic in nature and may 
be difficult to optimize in the context of larger panels. While their expression patterns 
are likely of great interest, they inevitably must be considered last as greater 
importance lies in establishing cell lineages before their possible phenotypes.  
 Once the list of markers is identified and prioritized, the second step in designing 
a high-dimensional panel is to match markers with available fluorophores. Assigning 
marker/fluorophore combinations is not an exact science but two important factors 
must be considered: a) Fluorophore brightness. The brightest fluorophores should be 
paired with low expression markers, either because a low number of molecules are on a 
single cell, or the marker is only expressed by a small subset of cells. In contrast, dim 
fluorophores should be assigned to high expression markers. Determining fluorophore 
brightness can be achieved by using a stain index, which compares the relative 
brightness of each fluorophore on a given flow cytometer132. b) Spillover between 
detector channels. Detector channels that measure similar wavelengths experience this 
phenomenon most often (for example B610 and G610 that measure 610nm to 620nm 
wavelengths)131. Signal spillover from one detector channel into another leads to 
spreading error (called spillover spreading error, or SSE) in the receiving channel and 
increases exponentially with intensity of the original signal133. SSE decreases sensitivity 
for detection of positive signal in the receiving channel and therefore must be avoided 
as best as possible. To account for SSE, a spillover spreading matrix (SSM) should be 
consulted. This matrix is unique to a given cytometer, and reveals detector channel 
interactions that experience SSE133. For channels that cause more spillover, low 
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expression markers should be assigned to those fluorophores. For a channel that 
receives spillover from another, highly expressed discrete markers or markers expressed 
on different cell types should be assigned when possible.  
 Finally, the third panel design step is to titrate antibodies and test panel 
iterations to determine the optimized final panel. Antibodies must be titrated and used 
at an optimal titer to achieve ideal separation between positive and negative 
populations without using excess reagent132. Panel iterations are then performed 
starting with a subset of lineage markers, mainly those deemed “high priority” to 
determine whether there are any issues with spillover or compensation131. If not, this 
original iteration becomes the backbone that further iterations are built off of. Proper 
single stain controls are also crucial at this step to generate accurate compensation. 
Single stains should be as bright or brighter than the signal detected on cells when 
applying the full panel134. Antibodies can then be added incrementally to assess whether 
their addition leads to disruptions with panel sensitivity for all markers. The result of the 
iterative process is a final panel that includes all desired markers and demonstrates 
sensitivity for each marker.  
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Chapter 2: Determining Adaptive Immune Correlates of Acute 
HBV Control 
 
Due to the fact that the rate of progression to CHB differs largely based on age (5-10% 
of adults and 90-95% of children), effective adaptive immune responses are likely 
extremely important determinants of outcome. However, the precise productive 
immunologic functions that fail during an acute HBV infection and lead to the 
progression of CHB are still unclear. Our goal is to determine adaptive correlates of 
acute HBV control that can be used to inform a more effective functional cure. 
 
2.1 Current Limitations to HBV Studies and Description of the MACS 
Cohort  
 
Although many studies of the immune response to HBV have been performed to date, 
these analyses often suffer from limitations in comprehensive understanding. These 
limitations mainly stem from the fact that acute HBV infection cohorts are uncommon. 
This is because the majority of acutely infected individuals are unaware of their 
infection status since most acute HBV infections are asymptomatic. Only a small subset 
of acute subjects experience symptoms including jaundice and fatigue50. As a result, 
acutely infected HBV cohorts often compare symptomatic acute infection to a separate 
group of CHB subjects who have been infected for many years. These comparisons are 
problematic for making conclusions regarding productive immune responses in acute 
HBV because what happens in symptomatic acute infection may not reflect the immune 
response during asymptomatic cases. Also, immune responses in CHB subjects after 
years of chronic infection may not represent the immunologic failures that occurred 
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during the acute phase which led to establishment of a chronic infection. Overall, there 
is a lack of longitudinal sampling in HBV infected individuals, leading to the inability to 
uncover accurate correlative measures associated with HBV control. 
 In addition, only recently have immunological studies begun to interrogate at the 
high-dimensional level antigen-specific responses in HBV subjects. Somewhat 
surprisingly, no known study to date has incorporated both B cell and T cell analysis into 
the same HBV samples, leading to a lack of understanding of the interplay between the 
cellular and humoral adaptive immune responses during HBV infection. To address 
these issues, we first sought access to samples from the Multicenter AIDS Cohort Study 
(MACS), which has longitudinal sampling and well-defined incident hepatitis B infection. 
 MACS was established in 1984 as a prospective multicenter study following MSM 
at risk of HIV infection135. In a more recent retrospective study, Falade-Nwulia et al. 
identified a subset of individuals participating in the greater MACS cohort who 
experienced an incident HBV infection136. These individuals were followed every 6 
months throughout their participation in MACS and therefore have longitudinal 
sampling prior to, during an acute HBV infection, and after outcome of infection is 
determined (>6 months after proposed exposure date). Our study will include the 
subset of these men who have PBMCs available at these three time points. Thus, there 
are 76 men with incident HBV of whom 22 developed CHB and 54 matched men (2-3 per 
CHB subject) who controlled their infection (Table 2.1). Subjects are matched on sex (all 
male), age, HIV status, CD4 counts (if HIV infected), and time samples have been stored 
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in the repository. Of the 22 subjects who developed a chronic infection, 13 are HIV-
infected and 9 are HIV-uninfected.  
Use of samples from the MACS cohort will allow us to address many of the issues 
listed above, specifically, the prospective nature of the cohort and subsequent detection 
of incident HBV infection allows for analysis of subjects with a more typical 
asymptomatic acute HBV infection course. In addition, subjects were followed 
longitudinally and therefore samples from an acute infection and after outcome can be 
compared within the same subject, allowing for potential immune correlates of 
protection to be identified. Finally, the longitudinal aspect allows examination in those 
with CHB close to acute infection and after the chronic state has been established. With 
access to such a unique cohort of HBV infected subjects, we next aimed to establish 
comprehensive tools to study the adaptive immune response to HBV infection. 
 
2.2 Development of High-Dimensional Flow Cytometry Panels for 
Immunologic Assessment in HBV 
 
In order to obtain as much immunologic information as possible from our study, we 
designed two comprehensive high-dimensional flow cytometry panels targeting B cell137 
and T cell phenotypic analysis (Table 2.2 & 2.3). In addition, both strategies incorporate 
a method to assess antigen-specificity through ex vivo tagging of HBsAg-specific B cells, 
or in vitro HBV peptide pool stimulation of T cells. Described below is the rationale for 
development of the panels and optimization of each panel with multiple non-MACS 
acute and CHB subjects. 
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2.2.1 High-Dimensional Characterization of B cells in Chronic Infection 
B cells are an important cell type in the prevention and/or control of infections through 
production of antibodies, professional antigen presentation, and secretion of 
cytokines138. During acute HBV infection, B cells are responsible for the production of 
antibodies against HBV envelope protein, HBsAg. Induction of anti-HBsAg (anti-HBs) is 
considered the clinical indication of recovery from an acute HBV infection, and 
prophylactic induction of anti-HBs is the protective mechanism of the HBV vaccine40,50. B 
cells also help to maintain control of HBV infection after resolution as shown by HBV 
reactivation in studies using CD20+ depleting rituximab for treatment of hematologic 
malignancies90–92. Although B cells are known to be an important cell type during HBV 
infection, it still remains unclear how these functions fail in an acute infection and lead 
to 5-10% of adults and 90-95% of children developing a chronic infection38. For this 
reason, we developed the panel described here to provide a comprehensive tool to 
study global and antigen-specific B cells during HBV infection. 
B cells can be defined by their expression of CD19 and CD20 (Figure 2.1A). We 
included a dump channel which enables the exclusion of CD3+ T cells, CD14+ monocytes 
and dead cells in order to increase our resolution between CD19+CD20+/- B cells and 
CD19-CD20- cell types (Figure 2.1A). In our panel we observed a population of dye 
aggregates in some phenotypic markers (CD39 and CD43), and thus excluded these 
aggregates before further analysis of B cells131,139 (Figure 2.1A). 
 B cells originate in the bone marrow where they generate a functional B cell 
receptor (BCR)140. After leaving the bone marrow, immature transitional B cells further 
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mature into antigen-inexperienced naïve B cells in the periphery141. Upon antigen 
exposure, naïve B cells are activated and further differentiate either through germinal 
center (GC) dependent or independent pathways142,143. The fate of a naïve B cell to 
enter a GC is dependent on its primary BCR affinity for antigen, with the highest affinity 
cells immediately differentiating into antibody-secreting plasmablasts in a GC 
independent manner, while lower affinity cells enter the GC and undergo affinity 
maturation144. The GC independent process results in the differentiation of short-lived 
plasmablasts or memory B cells that produce a rapid response with overall low or 
medium affinity antibodies against the respective pathogen145. Cells that enter the GC 
undergo class-switching and multiple rounds of somatic hypermutation (SHM) that leads 
to the selection of high-affinity B cell clones. High-affinity GC B cells egress from the GC 
as either short-lived plasmablasts, long-lived plasma cells or long-lived memory B 
cells146. Although the mechanisms underlying post-GC B cell fate decisions need further 
investigation, it is thought that both temporal factors and BCR affinity may play a role142. 
 The panel described here includes markers to distinguish many of the B cell 
developmental stages, with a focus on identifying antigen-specific memory B cells. 
Transitional B cells can be reliably determined as CD10+ and are gated out to focus 
analysis on mature B cells147 (Figure 2.1A). CD10- mature B cells can be further divided 
into plasmablasts (CD24-CD38hi) and non-plasmablasts based on the expression pattern 
of CD24 and CD38 (Figure 2.1B). Plasmablast populations are transient in the periphery 
and are often upregulated as a result of infection or vaccination19. Non-plasmablasts 
comprise unswitched and class-switched B cells based on the expression or lack of IgD 
 35 
and IgM. Class-switched cells that are IgM-IgD- are indicative of memory B cells derived 
from a GC, likely including multiple rounds of somatic hypermutation (SHM), and 
therefore have increased potential to induce productive antibody-mediated effector 
functions146. In contrast, unswitched B cells contain several subsets which can be 
differentiated by the expression of IgD, IgM and CD27148. Naïve B cells express both IgM 
and IgD but lack CD27 (Figure 2.1B), which is often used as a memory B cell marker. 
However, in certain circumstances CD27 alone is not a singularly reliable marker for 
memory B cells149. Furthermore, the IgD+CD27+ population contains either marginal 
zone (MZ) B cells (IgM+) or IgM-IgD+ memory B cells (Figure 2.1B). The development and 
function of IgD-only memory B cells remains elusive and awaits further 
clarification150,151. Peripheral MZ B cells are a unique population resembling splenic MZ 
B cells although their origin has not been definitively clarified152. MZ B cells possess 
“innate-like” polyreactive low-affinity BCRs and are important for glycan-specific 
antibody responses153. Patients undergoing splenectomy exhibit reduced levels of 
peripheral MZ B cells and show increased susceptibility to bacterial infections154. Finally, 
unswitched B cells contain a subset of IgD- cells which show high expression of IgM and 
are defined as IgM-only memory B cells 148,152 (Figure 2.1B). 
Although most markers in this panel are aimed at distinguishing conventional B 
cell subsets (B2), we also included markers associated with non-classical B1 B cells (CD43 
and CD5) (Figure 2.1C)155–158. This B cell subset is considered “innate-like” and produces 
T cell-independent, polyreactive, low-affinity IgM antibodies155. It has also been shown 
that human B1 cells play an unexpected role in immunosuppression as a source of anti-
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inflammatory cytokine IL-10155.  Although the exact definition of B1 B cells in humans 
remains elusive, multiple studies have aimed to address the best gating scheme to 
define this population, and our panel will contribute to resolve these issues156–158. B1 B 
cells are gated here as CD27+CD43+ on non-plasmablasts due to the overlapping 
expression of CD27 and CD43 on plasmablasts, which has been shown to contaminate 
the putative B1 B cell subset (Figure 2.1C)157,158. This population is further distinguished 
by expression of IgM and IgD, with a subset of cells IgM+ and/or IgD+. B1 B cells can also 
produce low-affinity IgA, and IgM-IgD- cells are likely IgA+ 155. CD5 was originally used as 
the primary marker to classify human B1 cells similar to mice, but it has become 
increasingly clear that in humans, CD5 is also expressed on a number of additional B cell 
subsets including pre-naïve, transitional, and even activated conventional B cells159. 
Therefore, identification of B1 cells here is not based on CD5 expression. However, 
inclusion of this marker allows for the capability to monitor CD5 expression on B1 cells, 
which has been suggested to contribute to downregulation in BCR signaling in this 
population, and appears higher on B1 B cells compared to other B cell and non-B cell 
subsets in chronic HBV subjects (Figure 2.1C)160. Examining the dynamics of these cells 
during chronic infection will provide unprecedented insight into their possible roles in 
the development of chronic disease. 
Functional subsets of conventional class-switched and unswitched memory B 
cells can be further refined using CD21 and CD27. In the field of chronic infections, CD21 
and CD27 alone are often used to distinguish naïve and memory B cell subsets. 
However, this analysis leads to complications with the CD21+CD27- population, which is 
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typically described as naïve B cells and excluded from memory analysis, but also 
contains a subpopulation of memory B cells known as intermediate memory (IM)161. In 
addition, naïve B cells have been shown to downregulate CD21 in autoimmune diseases 
and chronic infections, which may lead to contamination of the atypical memory 
phenotype (CD21-CD27-)162–164. Here, we further characterize the maturation state of 
switched memory B cells to examine intermediate memory (IM, CD21+CD27-), resting 
memory (RM, CD21+CD27+), activated memory (AM, CD21-CD27+), and atypical memory 
(AtM, CD21-CD27-) subsets (Figure 2.2A). This classification of memory B cell subsets is 
commonly used to characterize memory B cells in chronic infections including malaria, 
TB, HIV, HCV and HBV98,99,104,105. Chronic subjects have been shown to exhibit elevated 
levels of global as well as antigen-specific AtM B cells compared to healthy controls, and 
these AtM B cells appear to be less functional than other memory subsets104. Figure 
2.2A shows our observation of a similar trend with the increased frequency of AtM B 
cells identified from the class-switched IgM-IgD- population in chronic HBV subjects 
compared to a healthy control.  
A leading hypothesis as to the cause of chronic infections is that prolonged 
exposure to antigen leads to functional impairment of adaptive immune cells and 
ultimate persistence of infection165. T cell exhaustion has been studied in depth in 
chronic infections, and only recently has the idea of B cell exhaustion also been 
suggested. To address this possibility, our panel includes multiple markers to assess the 
functional capacity of global and HBV-specific B cells during HBV infection. For example, 
AtM B cells are characterized by increased expression of a number of exhaustion 
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markers, including, but not limited to, PD-1, FcRL5, CD11c, CD22 and CD32, all of which 
have been included in this panel104. As shown in Figure 2.2B, these exhaustion markers 
are upregulated on AtM B cells compared with other memory subsets in chronic HBV 
subjects. Through incorporation of many exhaustion markers, this panel allows for 
comprehensive analysis of the dynamics of global and antigen-specific AtM B cell 
phenotypes throughout the course of chronic infections. 
Chemokine receptors are important surface proteins that guide trafficking of 
immune cells in response to chemokine expression gradients166. In order to assess the 
capability of B cells to traffic to different sites during infection, we included analysis of 
CXCR5 and CXCR3 in this panel (Figure 2.3A). CXCR5+ cells traffic to the lymph node in 
response to expression of CXCL13 produced by follicular dendritic cells in the GC, and 
once there, encounter cognate antigen and mount a productive immune response 
against a pathogen. CXCR3+ cells, in contrast, traffic to sites of inflammation in response 
to CXCL9-11 secreted by monocytes and fibroblasts at inflamed tissue sites167,168. It is 
unclear whether trafficking of HBV-specific B cells to sites of inflammation such as the 
liver is necessary for a productive response against HBV, but upregulation in CXCL9-11 
has been shown in the liver and is associated with CXCR3+ hepatic infiltrates in HCV 
infection169,170.  
The costimulatory activation marker CD86 was included in the panel in order to 
determine the activation status of B cells during infection (Figure 2.3A). CD86 is 
constitutively expressed on B cells but is upregulated upon B cell activation and will help 
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determine the functional status of global as well as HBV-specific B cells within this 
panel171. 
Regulatory molecules BTLA and CD39 were included in the panel to examine the 
inhibitory status of HBV-specific and global B cell subsets during HBV infection (Figure 
2.3A). BTLA is expressed on B cells and upon binding its ligand recruits negative 
regulator SHP-1 that decreases downstream BCR signaling172. CD39 is an ectoenzyme 
that works in concert with CD73 to produce inhibitory ADO and IL-10, and CD39 
expression on B cells is associated with a B regulatory (Breg) phenotype173. All markers 
are shown in Figure 2.3A to have differential expression patterns between CD19+ B cells 
and CD19- non-B cells. One marker, CD22, did not demonstrate clear differential staining 
upon full panel analysis necessitating staining with an FMO control which showed a shift 
in the CD22+ population with full panel staining compared to FMO (Figure 2.3B).  
In summary, we describe here a comprehensive 24-color flow cytometry panel to 
study global and antigen-specific B cells, their subsets, and phenotypes in humans with 
chronic infections. Our B cell panel enables B cell analysis at unprecedented depth and 
holds promise to uncover new patterns and dynamics of B cell subsets and phenotypes 
that are either beneficial or detrimental in the progression of chronic infections. The 
added ability to incorporate dual-labeling antigen-specific probes (described below) 
increases the power to make relevant pathogen-specific conclusions regarding B cell 




2.2.2 Optimization of ex vivo HBV-Specific B cell Tagging 
An important goal for development of our B cell panel was to incorporate 
antigen-specificity into our analysis of memory B cells in HBV infection. To identify HBV-
specific B cells, a dual labeling strategy that has been previously published was 
employed98,105. Briefly, we obtained recombinant small HBsAg genotype C, manually 
conjugated to one of two fluorochromes, Dylight 550 or Dylight 650, from Gilead174. 
Dual staining was desired as it has been shown to increase the sensitivity of detecting 
low frequency antigen-specific B cell populations175,176. BCRs specific to small HBsAg will 
bind the probe-fluorophore reagent in order to tag HBsAg-specific B cells. 
Optimization of HBsAg-specific probes was performed using cryopreserved 
PBMCs from HBV unexposed healthy donor leukopacks (LPs) and a healthy subject 
followed throughout the course of their HBV vaccination series with Energix-B (AC51, 
Figure 2.4A)177. AC51 was selected as a positive control subject based on a strong 
response to vaccination as signified by production of antibodies against HBsAg (Figure 
2.4B). HBsAg Dylight 550 and HBsAg Dylight 650 were first titrated using half-log 
dilutions (equal concentrations of each Dylight reagent) on HBV unexposed healthy 
donor leukopack (LP) PBMCs (Figure 2.4C). Circulating HBV-specific B cells should not be 
detected in these samples, and they were therefore used as a negative control to find a 
range of concentrations that would limit non-specific background staining. The range 
between 0.2ug-0.063ug per 50uL staining reaction was found to have low background 
and these concentrations were tested on AC51. To determine which probe 
concentration was optimal, percent HBV-specific B cells for healthy LPs, AC51 (D189) 
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and three CHB subjects were examined (Figure 2.4D). There was little difference 
between the detection of HBV-specific B cells in the healthy LPs between probe 
concentrations, but a decrease in percent HBV-specific cells was observed in AC51 with 
the lower probe concentration. Therefore, 0.2ug per 50uL staining reaction was 
determined as the ideal concentration for HBsAg Dylight 550/650 reagents in the panel. 
Several timepoints were then sampled from AC51 in order to ensure that an expected 
spectrum of frequencies for HBsAg-specific B cells was observed to provide confidence 
that accurate detection of very low frequencies of HBsAg-specific B cells was possible 
(Figure 2.4E).  
To confirm that HBsAg-specific B cells being detected were truly HBV-specific, 
HBsAg Dylight550/Dylight650 double positive cells were sorted and differentiated for 14 
days in the presence of CD40L expressing cells, IL-2, and IL-21, as previously 
described178. Supernatants were collected and anti-HBs ELISA was performed on Dylight 
double positive B cells, Dylight double negative B cells, and CD40L expressing cells only. 
Only cells sorted from the double positive population produced anti-HBs antibodies, 
confirming their specificity to HBV and ability to be detected with the HBsAg probes 
(Figure 2.4F).  
In the context of the full panel, dual positive staining can be detected in both 
chronic HBV subjects as well as vaccinated individuals, but frequencies of circulating 
HBsAg-specific B cells are low (0.01%-0.04% circulating CD19+ B cells), as previously 
described (Figure 2.5A)98,105. Interestingly, a significant fraction of HBV-specific B cells 
from chronic subjects were unswitched (IgD+ and/or IgM+), and further identified as 
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naïve B cells (IgD+CD27-). Those that were IgD+CD27+ were mainly marginal zone B cells 
(Figure 2.5B). A detailed assessment of HBV-specific B cell phenotypes for CHB vs 
healthy vaccinated is shown in Figure 2.5C-D. It is important to note from this analysis 
that our panel enables rigorous gating strategies in order to ensure precise examination 
of populations of interest, which in our case are memory B cells.  
 
2.2.3 Comprehensive Assessment of T cells in Chronic Infection 
T cells play an important role in the control and elimination of pathogens179,180. 
However, when their protective functions are dysregulated it can lead to the 
development of disease such as chronic infection, cancer, and autoimmunity181,182. The 
ability to profile T cell phenotypes and functions in a high-dimensional fashion allows for 
comprehensive understanding of T cell dynamics in health and disease.  
Although it is well established that T cells play a vital role in control of HBV 
infection, it remains unclear what T cell functions fail in the progression to CHB183. We 
developed the following panel in order to identify global and antigen-specific T cell 
functions important for control of HBV infection. Here, we report a comprehensive 30-
parameter flow cytometry panel with the capability to assess detailed differentiation, 
effector functions including activation and cytokine production, and inhibitory status of 
CD4+, CD8+ and T regulatory cells (Tregs).  
 All T cells subsets can be reliably identified by their expression of CD3 and 
further described by expression of either CD8 or CD4 (Figure 2.6A). CD8+ T cells are the 
main effector T cells, characterized by their ability to lyse infected cells through release 
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of perforin and granzyme upon recognition of cognate antigen. CD4+ T cells in contrast 
perform helper functions, mainly cytokine production and co-stimulation to aid 
differentiation and drive both CD8+ T cell and B cell function184. One subset of CD4+ T 
cells are Tregs, which can be identified as CD4+CD25+CD127- (Figure 2.6B)17. Tregs act as 
negative immune regulators and function to suppress effector immune cell function by a 
variety of mechanisms. Through upregulation of the high-affinity IL-2 receptor complex 
(CD25, CD122 and the common gamma chain), Tregs outcompete effector T cells for IL-
2, an important growth factor for T cell maintenance. Tregs also produce 
immunosuppressive cytokines IL-10 and TGFβ, as well as upregulate a number of co-
inhibitory receptors including CTLA-4185. Finally, Tregs express ectoenzymes CD39 and 
CD73, which together produce inhibitory ADO186,187. We included CD39 in our panel to 
help distinguish Tregs (Figure 2.6B) as well as to determine whether other T cell subsets 
aberrantly upregulate the inhibitory molecule in the context of chronic infection. 
 T cells undergo maturation in the thymus and enter the periphery as mature 
naïve T cells188. Upon antigen exposure they differentiate into effector or memory 
cells189. Memory subsets each have distinct functions and are identified in the periphery 
with a combination of surface markers CCR7 and CD45RA as follows: Naïve 
(CCR7+CD45RA+), T effector memory (Tem, CCR7-CD45RA-), T central memory (Tcm, 
CCR7+CD45RA-) and T effector memory CD45RA expressing (Temra, CCR7-CD45RA+)190. 
Expression of costimulatory CD27 and CD28 can further distinguish memory subset 
differentiation status (Figure 2.6C)190.  
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 The panel described here includes multiple markers to detect T cell activation 
upon recognition of cognate antigen. CD69 is an early activation marker important for 
identifying low frequency cytokine producing cells after antigen-specific stimulation in 
vitro191,192. In addition, we included the co-stimulatory molecule OX40 in the panel due 
to its role in promoting T cell survival and proliferation after antigen-specific stimulation 
(Figure 2.7A)193. Interestingly, OX40 was observed to be upregulated on HBV-specific T 
cells and stimulation with an OX40 agonist was shown to augment HBV-specific T cell 
responses194. We also included the co-stimulatory molecule CD154 (CD40L) (Figure 
2.7B). CD154 is expressed on all activated CD4+ antigen-specific T cells and is a crucial 
co-stimulatory molecule that binds CD40 on B cells to aid the development of high-
affinity antibody responses in the germinal center (GC) (Figure 2.7B)195,196. 
  In addition to activation markers, we included multiple cytokines (TNF, IFNy, IL-2 
and IL-21) and the degranulation marker CD107a in our panel to assess effector 
functions generated as a result of antigen-specific activation (Figure 2.7B). Cytotoxic 
CD8+ T cells are important effector cells. Upon recognition of their cognate antigen, lytic 
vesicles containing perforin and granzyme are triggered to release their contents. 
CD107a (LAMP-1) is also located within lytic vesicles and upon degranulation is 
transiently expressed on the cell surface and allows for the identification of 
degranulated cells197. TNF is a pro-inflammatory cytokine produced early after activation 
and helps recruit neutrophils and monocytes to the site of infection as well as plays a 
role in tissue remodeling190,198. IFNy is an antiviral cytokine associated with a Th1 helper 
CD4+ T cell response and effector CD8+  T cell responses199. In the context of HBV 
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infection, TNF and IFNy production from effector CD8+ T cells has been shown to 
mediate non-cytopathic clearance of HBV DNA from infected hepatocytes62. IL-2 is an 
important cytokine for T cell differentiation and survival. Mainly produced by CD4+ and 
CD8+ T cells, it provides survival and proliferation signals to lymphocytes200. Finally, IL-21 
is a critical cytokine for T follicular helper cell (Tfh) mediated maturation of B cells to 
produce high-affinity antibodies201. Strong T cell stimulatory signals provided by phorbol 
myristate acetate (PMA) and Ionomycin can stimulate T cells in vitro to express and 
produce co-stimulatory molecules, degranulation markers and cytokines. Therefore, we 
utilized PMA/Ionomycin stimulation to optimize our panel and detect our cytokines of 
interest (Figure 2.7A-B)202. 
 Chemokine receptors are important surface proteins that guide trafficking of 
immune cells in response to chemokine expression gradients166. We included CXCR5 and 
CXCR3 in our panel to assess trafficking of global and antigen-specific T cells. CXCR5+ 
cells traffic to the lymph node in response to expression of CXCL13 produced by 
follicular dendritic cells in the GC while CXCR3+ cells instead traffic to sites of 
inflammation in response to CXCL9-11 secreted by monocytes and fibroblasts at 
inflamed tissue sites (Figure 2.8A)167,168.  
 Checkpoint inhibitory molecules normally function to downregulate immune 
responses after effector functions have occurred to avoid overexuberant immune 
activation203. However, in the context of cancer and chronic infection, persistent antigen 
exposure aberrantly drives the upregulation of inhibitory molecules leading to cellular 
exhaustion phenotypes204. To assess the degree of T cell dysfunction in global and 
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antigen-specific T cells during chronic viral infection, we included multiple inhibitory 
markers PD-1, TIM-3, CTLA-4, and TIGIT in our panel. These inhibitory molecules were all 
chosen for their current clinical significance, with strategies to block checkpoint 
inhibition through each of these markers currently being tested in clinical trials (Figure 
2.8B)205.  
 Recent work has shown in chronic infections that T cells exhibiting an exhausted 
phenotype are not all created equal. The combination of PD-1, CD127 and transcription 
factor TCF1 expression help determine multiple stages of memory cell exhaustion77,206. 
TCF1 is a transcription factor and chromatin remodeling protein in the canonical WNT 
signaling pathway and shows varying expression throughout the course of T cell 
differentiation207. Expression of TCF1 indicates the proliferative capacity of T cells, with 
higher expression occurring in naïve and memory cells capable of proliferating. For 
exhausted T cells in chronic infection, PD-1+CD127+ cells often share similarities with 
conventional effector T cells but show signs of exhaustion through PD-1 expression and 
functionally less ability to proliferate or produce cytokines. However, these cells do 
express TCF1 and therefore maintain minimal effector function208. PD-1+CD127- cells on 
the other hand typically lack TCF1 expression and show upregulation of additional 
exhaustion markers. These cells are considered terminally exhausted with no 
proliferative or cytokine production capacity74,206,209. Figure 2.8C shows the differential 
expression of PD-1 and CD127 on CD8+ memory T cells and subsequent TCF1 expression 
on each subset. In the CHB subjects assessed, TCF1 expression is high in both CD127+PD-
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1+ and CD127-PD-1+ populations, but decreased expression is observed in a subset of 
PD-1- cells, demonstrating the ability of our panel to assess these differences. 
 Finally, in order to detect more detailed T cell differentiation states related to 
chronic infection, we included CD161 and KLRG1 in our panel. CD161 is a C-type lectin 
receptor mainly expressed on NK cells, but also expressed on a subset of T cells. On T 
cells, intermediate expression is associated with productive effector function, while high 
expression instead represents a subset of dysfunctional cells (Figure 2.8D)210.  In chronic 
HCV and HBV infection, intrahepatic virus-specific CD8+ T cells were found to express 
CD161 on Tem cells, but these cells proliferated poorly in vitro211. KLRG1 is also primarily 
an NK cell receptor, but on T cells it is classically associated with antigen-experienced T 
cells that have undergone senescence212. The senescent phenotype is supported by the 
observation that frequency of KLRG1 expression increases with age. However, KLRG1 
also possesses an ITIM motif and is considered a putative co-inhibitory receptor (Figure 
2.8E)212.  
 Taken together, our comprehensive T cell panel offers the unique opportunity to 
assess multiple T cell effector functions including activation, cytokine production, 
trafficking and exhaustion as well as provides the chance for unprecedented assessment 
of T cell differentiation states associated with productive and/or dysfunctional 
responses in chronic infection. The panel has been optimized not only with robust, non-
specific activation of PMA/Ionomycin, but validated using both acute and chronic HBV 
subjects exposed to overnight peptide pool stimulation with pools composed of 
overlapping peptides from three HBV-specific antigens: HBsAg, HBcAg and HBV pol  
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(see 2.2.4 Optimization of in vitro Peptide Pool Stimulation for HBV-specific T cell 
Identification below). The panel described here has the ability to identify functional 
antigen-specific T cells through activation and cytokine production, as well as assess 
global and antigen-specific phenotypes associated with productive and/or dysfunctional 
immune responses. 
 
2.2.4 Optimization of in vitro Peptide Pool Stimulation for HBV-specific T cell 
Identification 
In order to identify HBV-specific T cells, we sought to optimize an in vitro peptide pool 
stimulation strategy that would enable us to assess T cell responses to multiple HBV 
antigens. To this end, we designed three overlapping peptide pools consisting of 
peptides 15 amino acids in length with an 8 amino acid overlap that span the entire 
protein sequence for large HBsAg (Surface pool, also containing the sequence for 
medium and small HBsAg), HBeAg/HBcAg (Core pool, containing peptides that cover 
both the pre-core and core sequences) and HBV pol (Pol pool) (Table 2.4) 
 PBMCs from two acute HBV subjects and two CHB subjects were stained for flow 
cytometric analysis of activation and cytokine production after overnight peptide pool 
stimulation (Figure 2.9A). Consistent with the literature, cytokine production from acute 
HBV subjects was robust while minimal cytokine production was observed in CHB 
subjects (data not shown)213. Interestingly, cytokines in acute subjects came exclusively 
from CD4+ T cells, with no production observed from CD8+ T cells. As CD8+ T cell 
responses are reported in the literature, we hypothesized that either our intracellular 
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cytokine staining (ICS) assay was not sensitive enough to detect possible low-frequency 
CD8+ T cell responses, our peptide pools were not optimized for CD8+ T cell stimulation, 
or that our timing for HBV peptide pool stimulation was not ideal to detect CD8+ T cell 
cytokine production. 
 To address this discrepancy, we performed an ELIspot assay on isolated CD8+ T 
cells from one acute HBV subject and observed spot formation below background levels 
for cells stimulated with all three peptide pools (Figure 2.9B). As ELIspot is known to be 
more sensitive than ICS in detecting cytokine production after T cell stimulation214, we 
concluded that lack of sensitivity in our ICS assay was not the cause of no observable 
CD8+ T cell cytokine production since we also did not observe responses in our ELIspot 
assay with similar timing of stimulation between the two assays. 
 While our peptide pool stimulation protocol is an overnight stimulation of 14-16 
hours, most ICS experiments performed on HBV samples in the literature occur after an 
8-10 day expansion of PBMCs with peptide pools before a secondary overnight pulse 
stimulation. To determine whether our lack of CD8+ T cell responses was due to timing, 
or if the peptide pools were not optimized to detect CD8+ cytokine production, we 
performed a 10 day expansion on one acute HBV subject prior to overnight pulse 
stimulation with each HBV peptide pool. We found that 10 day expansion did in fact 
allow for detection of HBV-specific CD8+ T cell responses (Figure 2.9C). Therefore, we 
concluded our peptide pools can in fact stimulate CD8+ T cell responses but the timing of 
stimulation is not ideal to detect HBV-specific CD8+ T cell cytokine production. Although 
useful in determining that our experimental methods work, we must acknowledge that 
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the optimization here was performed on only one to two acute HBV subjects. It remains 
possible that in our larger cohort, detection of CD8+ T cell cytokine production will be 
possible in a subset of subjects after overnight stimulation. In addition, our inclusion of 
multiple activation markers in the panel will allow for identification of antigen-specific 
CD8+ T cells that are activated after peptide pool stimulation regardless of whether they 
are functionally able to produce cytokines. 
 
2.3 Perspectives and Future Directions 
 
The study described within this chapter has been designed as a first of its kind to 
uncover adaptive immune correlates of acute HBV infection control. To date, it remains 
unclear why many adults who acquire an acute HBV infection are able to control the 
infection readily while a small subset progress to CHB. Likely, there is a crucial role 
played by productive adaptive immune responses that has yet to be fully understood.  
 Through access to a longitudinally followed cohort with well-defined incident 
HBV infection, as well as the development of two comprehensive flow cytometry panels 
to profile at the high-dimensional level both B cell and T cell responses, we aim to 
uncover antigen-specific and/or global adaptive immune cell parameters that differ in 
the acute stage of infection and correlate with productive outcomes.  
 Efforts are currently ongoing to finish acquisition of our samples and analyze 





  HIV uninfected HIV Infected 
Outcome  Control Chronic Control Chronic 
Number of subjects  
(% total cohort) 
 22 (29%) 9 (12%) 32 (42%) 13 (17%) 
Sex  Male 22 9 32 13 





Table 2.2. High-dimensional B cell flow cytometry panel. 
 
Specificity Fluorochrome Purpose  
HBsAg Dylight 550/Dylight 650 HBV-specific B cell tag  
CD19 APC-H7 Lineage B cells  
CD20 BV786    
CD10 PE-Cy5 Differentiation B cells  
CD27 PE-CF594    
CD21 BUV496    
IgM AF700    
IgD BB790    
CD24 BUV395    
CD38 BUV661    
CD5 PE-Cy5.5    
CD43 BV605    
CD86 BUV737    
CXCR3 BV421 Trafficking  
CXCR5 PE-Cy7    
CD11c BB630 Inhibitory/Exhaustion Marker  
CD39 BV711    
PD-1 FITC    
FcRL5 BB660    
BTLA BB700    
CD22 BUV805    
CD32 BV750    
CD3/CD14 BV510 Dump  
Viability Live Dead Aqua Viability/Dump  
 
    
    
    
  
Subjects matched on age, HIV status, CD4 T cell count (for HIV infected) and time in repository. 
*Treatments include Iam, tdf, Iam/tdf, ftc/tdf, lam/ftc/tdf. 
 
Table 2.1. Characteristics of Multicenter AIDS Cohort Study Participants. 
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Table 2.3. High-dimensional T cell flow cytometry panel. 
 
Specificity Fluorochrome Purpose 
CD3  BUV496 Lineage T cells 
CD4  BUV805   
CD8 BV510   
CD45RA APC H7 Subsets T cells 
CCR7 BUV395   
CD25  BUV563   
CD127 PE Cy5   
KLRG1 PE CF594 Proliferative Capacity 
TCF1  AF488   
CD161 BV605   
CD27 BV786 Activation 
CD28 BV570   
CD69 PE Cy5.5   
CD40L  BV650   
OX40 BV711   
CXCR5 BB790 Trafficking 
CXCR3 PE   
PD-1 BUV661 Inhibitory/Exhaustion Marker 
TIM-3 BUV737   
CTLA-4 PE Cy7   
Tigit BB660   
CD39 BB630   
IFNy  BB700 Cytokines 
TNF BV750   
IL-2  BV421   
IL-21 AF647   
CD107a AF700   








Core Pool HBeAg, HBcAg 26 2ug/mL/peptide 
Polymerase Pool HBV Polymerase 120 2ug/mL/peptide 
Surface Pool HBsAg (L-, M-, S-) 56 2ug/mL/peptide 
Table 2.4. HBV Peptide Pools 
Overlapping peptides designed from HBV genotype A sequence. Each peptide is 15 amino 
acids in length with an 8 amino acid overlap. 
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Figure 2.1. Gating strategy for the 24-color panel to assess B cells in HBV infection. 
 
A. Gating of B cells from viable CD3-CD14- cells in PBMC is depicted. Dye aggregates were removed 
from analysis. Mature B cells were defined as CD10- B cells. B. CD10- mature B cells can be divided 
into CD24-CD38hi plasmablasts and non-plasmablasts (upper left plot). Non-plasmablasts can be 
further characterized based on their surface expression of Ig classes IgM and IgD. IgM/IgD double 
negative cells are defined as class-switched memory B cells. Surface expression of IgM, IgD, or in 
combination characterizes unswitched B cells (upper right plot). Unswitched B cells can be further 
delineated into naïve B cells (IgD+CD27+), IgM-only memory B cells (IgD-CD27+/-) and IgD+CD27+ 
cells (lower left plot). The latter population contains IgM+IgD+CD27+ marginal zone B cells and  IgM-
IgD+CD27+ IgD-only memory B cells (lower right plot). C. Gating of CD27+CD43+ non-classical B1 B 
cells within non-plasmablast cells is shown for chronic HBV patients (upper left plot). Gating on 
non-plasmablasts is important due to overlapping CD43 expression on plasmablast cells (upper 
right plot). B1 cells can be divided into unswitched (IgM+ and/or IgD+) or IgM-IgD- switched cells 
(lower left plot). CD5 expression is higher on B1 B cells compared with non-B cells, plasmablasts, 







Figure 2.2. Increased frequency of AtM B cells in CHB and higher inhibitory/exhaustion 
marker expression. 
 
A. Class-switched B cells can be further classified based on their expression of CD21 and CD27. 
Here, class-switched memory B cells are defined as follows: CD21+CD27- intermediate memory 
(IM), CD21+CD27+ classic resting memory (RM), CD21-CD27+ activated memory (AM), and CD21-
CD27- atypical memory (AtM). An increased frequency of AtM B cells is observed in CHB subjects 
compared to healthy controls. B. Expression levels of phenotypic markers associated with chronic 
infections were examined on the four memory B cell subsets, IM, RM, AM and AtM to show 
increased expression of all markers on AtM B cells in chronic HBV infection. Chronic HBV plots 




Figure 2.3. Unique expression of all phenotypic markers observed with full panel 
staining. 
 
A. Expression pattern of phenotypic markers on viable CD3-CD14- cells is shown. The marker CD19 
is used on the y-axis to visualize unique expression patterns of phenotypic markers on B cells. All 
plots show three concatenated CHB subjects. B. FMO control for CD22 shows sufficient separation 
of CD22+ B cells from non-B cells despite dim staining of CD22 BUV805. One chronic HBV subject 






Figure 2.4. Optimization of HBsAg Dylight probes to detect HBsAg-specific B cells. 
 
A. Timeline of sample acquisition throughout course of HBV booster vaccination with ENERGIX-B 
for healthy vaccinated subject AC51. Sampling occurred immediately before the first booster (D0), 
7 days after the first booster (D7), 32 days after the first booster (D32), 12 days after second 
booster (D47) and 7 days after third booster (D189). B. Plasma antibody titers against HBsAg (anti-
HBs) over time. Increase in anti-HBs from baseline shows response to vaccination. Dots indicate 
sample mean OD450 and are plotted against time points when samples were collected, arrows 
indicate when boosters occurred. Samples were run in duplicate, error bars=SD. C. Half-log 
titrations of HBsAg Dylight 550/650 probes on healthy HBV unexposed leukopak (LP) subjects (LPs, 
top row, 5 concatenated subjects) to determine probe concentrations with minimal non-specific 
background staining. Two concentrations of HBsAg Dylight probes with lowest background were 
tested on PBMC from AC51 D189 (bottom row) to confirm the detection of double positive HBV-
specific B cells. D. HBV-specific B cell frequencies from PBMC samples stained with either 
0.2ug/50uL or 0.063ug/50uL of the Dylight 550 and Dylight 650 labeled HBsAg probes. HBV-
specific B cells were defined as double positive for HBsAg probes. Data includes 5 healthy HBV 
unexposed donor LPs and 4 total HBV exposed individuals (1 healthy subject with HBV booster 
vaccination (AC51) and 3 chronic HBV (CHB) subjects). Black dots are CHB subjects that were only 
tested at one concentration. Colored dots show individual subjects at each concentration tested. 
Bar indicates median value of each group.  E. Time course analysis of AC51 to validate use of 0.2ug 
HBsAg Dylight 550/650 per 50uL staining reaction. HBV-specific B cells are detected at a greater 
frequency over time, with little non-specific background staining. F. HBsAg Dylight 550/650 
double positive cells were sorted and stimulated with CD40L expressing feeder cells, IL-2, and IL-
21 for 14 days. Supernatants were run on anti-HBs ELISA and the specificity of the HBsAg Dylight 
550/650 detection method was confirmed as only double positive cells produced anti-HBs. For 
staining reactions (C & E), HBsAg Dylight 550 and Dylight 650 were added at equal concentrations 
in 50uL staining reactions. Optimization was performed on a smaller panel of B cell markers for 
all figures, and plots were pre-gated on viable, CD3-, CD14-, CD19+, CD10-, 





Figure 2.5. HBV-specific B cell lineages and phenotypes  
 
A. HBsAg double positive cells within unswitched (first column) and class-switched (second 
column) subsets are shown for a healthy HBV vaccinated subject (top row) and chronic HBV 
patients (bottom row). B. HBsAg-specific B cells derived from unswitched B cells were overlaid on 
total unswitched B cells from the chronic HBV patients. The majority of unswitched CD27+ HBsAg-
specific B cells represent marginal zone B cells. C. Unswitched and class-switched HBV-specific B 
cells from 3 chronic HBV (CHB) subjects were concatenated and overlaid on total B cells in CHB to 
show expression patterns for each phenotypic marker included in the panel for all HBV-specific 
cells. D. Similar analysis was performed on all HBV-specific B cells from healthy vaccinated subject 






Figure 2.6. Gating Strategy for 28-color panel to assess T cell responses in HBV 
infection 
 
A. T cells are gated from live, single cell lymphocytes and can be distinguished by CD3+ staining. T 
cells are further delineated by their unique expression of CD4 or CD8. B. CD4+ T cells contain a 
population of CD25+CD127- T regulatory cells that have increased expression of CD39. C. Both CD4+ 
and CD8+ T cells contain naïve T cell populations (CD45RA+CCR7+) and memory subsets. Memory 
T cells are identified as: T central memory (Tcm, CCR7+CD45RA-), T effector memory (Tem, CCR7-
CD45RA-) and T effector memory CD45RA+ (Temra, CCR7-CD45RA+). Expression of CD27 and/or 
CD28 further distinguishes memory T cell subsets. Gating was performed on two concatenated 






Figure 2.7. PMA/Ionomycin stimulation upregulates activation, degranulation and 
cytokine production from T cells. 
 
A. Activation markers CD69 and OX40 are expressed upon strong stimulation with 
PMA/Ionomycin in both CD4+ and CD8+ T cells in a healthy subject. B. Memory CD4+ and CD8+ T 
cells produce all cytokines assessed by our panel upon stimulation with PMA/Ionomycin. 
Cytokines are plotted against co-stimulatory molecule CD154 (CD40L) for CD4+ T cells and 
degranulation marker CD107a for CD8+ T cells to simultaneously show activation and cytokine 
production. Cytokine production was assessed in a healthy subject. 
 
  A. 
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Figure 2.8. All phenotypic markers are detectable in the panel in the context of 
functionally relevant cell subsets. 
 
A. Chemokine receptors CXCR5 and CXCR3 are detected at higher frequencies in the memory CD8+ 
T cell compartment (red) compared to naïve cells (blue). Plots show PBMCs from two 
unstimulated acute HBV subjects. B. Exhaustion markers included in the panel demonstrate 
differential expression on CD8+ T cells compared to CD8- T cells (top row) in two CHB subjects. 
Expression levels are also shown to differ between two acute HBV subjects (naïve = green, 
memory = orange) and two CHB subjects (naïve = blue, memory = red)(bottom row). PBMCs were 
stimulated with HBV peptide pools prior to acquisition. C. Expression of PD-1 and CD127 assessed 
on CD8+ memory T cells from two CHB subjects stimulated with HBV peptide pools (left plot). PD-
1+ cells indicate a partially exhausted state. TCF1 expression was then assessed on CD127-PD-1-, 
CD127-PD-1+, CD127+PD-1- and CD127+PD-1+ populations to determine further terminal 
exhaustion status (right quadrant). D. Differential expression of CD161 is shown on CD8+ Tem cells 
from two CHB subjects stimulated with HBV peptide pools compared to Tcm and Temra subsets. 
E. KLRG1 expression was observed in acute HBV subjects in the non-T cell compartment. While 
expressed on T cells, KLRG1 is primarily an NK cell marker and expression here confirms ability to 
detect the marker in the context of the full panel.  
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Figure 2.9. Overnight HBV peptide pool stimulation leads to CD4+ T cell cytokine 
production while 10 day expansion is necessary to elicit robust CD8+ T cell cytokine 
responses. 
 
A. PBMCs from two acute HBV subjects were rested 6 hours before stimulation with one of three 
HBV peptide pools for 16 hours overnight in the presence of brefeldin A and monensin. Plots show 
memory CD4+ or CD8+ T cells with both subjects and all HBV peptide pools concatenated. 
Overnight stimulation produces robust CD4+ T cell responses to HBV peptide pools but little CD8+ 
cytokine production. B. IFNy ELIspot was performed on isolated CD8+ T cells after 6 hour rest to 
determine whether more robust IFNy production could be observed with the more sensitive 
cytokine assay. Data are reported as IFNy spot forming colonies per 1 million cells and each dot 
represents one replicate well. Red line indicates limit of detection of the assay. Representative 
images from wells stimulated with each peptide pool are shown to the right. C. PBMCs from one 
acute HBV subject were rested 6 hours before stimulation for 10 days in culture with one of three 
HBV peptide pools and rIL-2. Half of the culture media with rIL-2 was replaced at days 3 and 7, 
then again at day 9 without rIL-2 replacement. On day 10 cells were restimulated for 16 hours 
with the same peptide pool they were expanded with. Plots show memory CD4+ or CD8+ T cells 










Chapter 3: Metabolic Programs Define Dysfunctional Immune 
Responses in Severe COVID-19 
 
It is unclear why some SARS-CoV-2 patients readily resolve infection while others 
develop severe disease. By interrogating metabolic programs of immune cells in severe 
and recovered COVID-19 patients compared to other viral infections, we identified a 
unique population of T cells. These T cells express increased VDAC1, accompanied by 
gene programs and functional characteristics linked to mitochondrial dysfunction and 
apoptosis. The percentage of these cells increases in elderly patients and correlates with 
lymphopenia. Importantly, T cell apoptosis is inhibited in vitro by targeting the 
oligomerization of VDAC1 or blocking caspase activity. We also observe an expansion of 
myeloid derived suppressor cells with unique metabolic phenotypes specific to COVID-
19 and their presence distinguishes severe from mild disease. Overall, the identification 
of these metabolic phenotypes provides insight into the dysfunctional immune response 
in acutely ill COVID-19 patients and provides a means to predict and track disease 
severity and/or design metabolic therapeutic regimens215. 
 
3.1 Immunometabolic Approach to SARS-CoV-2 Assessment  
We hypothesized that interrogation of immunometabolic phenotypes in COVID-19 has 
the potential to transcend traditional immune cell phenotyping and provide novel 
insights into distinct functional subsets. To this end, we developed a flow cytometry-
based proteomic and epigenetic approach that enables the interrogation of metabolic 
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programs at the single cell level (Figure 3.1). We focused on three main pathways to 
characterize the metabolic landscape of immune cells in COVID-19. First, the 
mitochondrial membrane proteins Voltage Dependent Anion Channel 1 (VDAC1) and 
Tomm20 were used as surrogates for mitochondrial mass and utilization of oxidative 
phosphorylation. Second, to evaluate the presence of glycolytic machinery used for 
glycolysis, the glucose transporter Glut1 and the rate limiting enzyme of glycolysis, 
Hexokinase II (HK2) were evaluated. Finally, the ability to utilize fatty acid oxidation was 
measured by the expression of carnitine palmitoyltransferase 1a (CPT1a). Expression of 
H3K27Me3 was included as a readout for histone methylation which is regulated at 
multiple levels by metabolites of the TCA cycle216. Using this approach, we identified 
distinct T cell and myeloid subsets in the PBMC of acutely ill COVID-19 patients (COVID-
A) that were not found in the PBMC of recovered COVID-19 patients (COVID-R) and 
patients with hepatitis C virus (HCV) and influenza viral infections. Furthermore, these 
cells provide important mechanistic insight into the immune dysfunction observed in 
COVID-A patients and the mechanism of pathogenesis 
 
3.2 Metabolically Distinct T cells in SARS-CoV-2 
The high dimensional flow cyotometry-based assay was performed on thawed PBMC 
from an IRB approved biorepository from patients admitted to the Johns Hopkins 
Hospital (Table 3.1). We initially focused on T cells within the PBMC given their 
importance in viral control. Using traditional immunological markers, we observed 
limited differences in T cell frequencies and phenotype, as previously described (Figure 
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3.2)127,217. Most notably, we detected an increase in the CD4:CD8 ratio and an increase 
in central memory (Tcm) CD4 T cells in COVID-A patients when compared to healthy 
controls (Figure 3.2B-C). In addition, when compared to healthy controls, we observed 
no differences in expression of the classical markers of T cell subsets CD45RA and CCR7 
(Figure 3.2E) or the activation markers CD69, Ki67, PD-1, or HLA-DR (Figure 3.2F). 
Likewise, levels of metabolic enzymes involved in glycolysis and fatty acid oxidation did 
not differ between the two groups (Figure 3.2G).  
In stark contrast, unbiased analysis of T cells employing the combined immune 
and metabolic markers dramatically segregated T cells from healthy controls and COVID-
A (Figure 3.3A). This unique population of T cells found in the COVID-A patients was 
characterized by robust upregulation of VDAC1 and the epigenetic mark H3K27me3 
(Figure 3.3A-B). H3K27me3 is regulated in part by a-ketoglutarate-mediated jumonji 
demethylases216, while VDAC1 is a mitochondrial membrane protein involved in 
metabolite transport, and has been associated with mitochondrial cell death signaling 
and lupus-like autoimmunity218,219. This phenotype was unique in its exclusive 
upregulation of mitochondrial proteins, without a concomitant upregulation of 
glycolytic machinery. Classically, upon T cell activation VDAC1 and H3K27me3 
expression increase along with the glucose transporter Glut1 and Hexokinase II (HKII), 
both of which support activation-induced glycolysis. This traditional activation signature 
was seen upon TCR stimulation of healthy PBMCs in vitro (Figure 3.3C). However, the 
unique population of H3K27me3hiVDAC1hi T cells in the PBMC of COVID-A patients differ 
from conventional recently activated T cells because they express relatively low levels of 
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Glut1 and HKII (Figure 3.3D). The H3K27me3hiVDAC1hi T cells were found both within the 
naive and memory T cell compartment (Figure 3.3D) and did not demonstrate 
enrichment for specific TCR clones (Figure 3.3E). Expanded analysis of 55 PBMC samples 
from 38 COVID-A patients (including sequential samples) revealed that these T cells 
were markedly upregulated (many exceeding 50% of total T cells) in COVID-A patients 
and were almost completely absent in healthy controls (Figure 3.3F). Interestingly, while 
not present in all of the patients queried, every COVID-A patient 70 years of age and 
older demonstrated frequencies of the H3K27me3hiVDAC1hi T cells which were 40% or 
greater in their PBMC (Figure 3.3G). Overall, these data reveal a distinct population of 
H3K27me3hiVDAC1hi T cells in the PBMC of COVID-A patients. The discordance in 
activation and metabolic phenotypes suggests that these T cells are dysfunctional.  
 
3.2.1 Unique H3K27me3hiVDAChi T cells Distinguish Acutely Ill COVID-19 Patients from 
Recovered Patients and Hospitalized Patients Infected with Influenza 
 
By interrogating metabolic programs using our immune-metabolic assay, we were able 
to identify a unique population of H3K27me3hiVDAC1hi T cells in COVID-A patients. We 
next wanted to determine if this population of T cells was unique to the COVID-A 
patients. To this end, we interrogated the PBMC of recovered COVID-19 patients (>28 
days from diagnosis, COVID-R) and patients with other viral infections to determine if 
this phenotype was simply a result of ongoing inflammation or general consequence of 
viral infection. PBMC were obtained and analyzed from patients with acute and chronic 
viral hepatitis C infection220, hospitalized with influenza infection221, and those who had 
recovered from COVID-19 (COVID-R)222 (Table 3.2). There appeared to be only subtle 
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differences between these groups in CD4+ and CD8+ T cell subsets as defined by 
traditional markers (Figure 3.2). Yet, when including metabolic markers in the analysis, 
the COVID-A patients’ T cells again segregated compared to other groups as shown by 
UMAP projections, indicating a distinct subset of T cells unique to COVID-A patients not 
accounted for by traditional markers (Figure 3.4A-C). H3K27me3hiVDAC1hi T cells were 
absent in both acute and chronic hepatitis C infection; however, they were present in a 
subset of both influenza and COVID-R patients (Figure 3.4D-E). 
Importantly, although T cells present in severe influenza infection and during 
recovery maintained elevated VDAC1 and H3K27me3 expression, clustering the 
H3K27me3hiVDAC1hi CD4 T cells by protein expression of all other markers included in 
the flow cytometry panel showed that these cells robustly clustered based on disease 
type, indicating qualitative differences in H3K27me3hiVDAC1hi T cells across disease 
status (Figure 3.4F). That is, even though T cells expressing H3K27me3 and VDAC1 were 
present in the PBMC of the influenza and COVID-R patients, they were distinct from the 
H3K27me3hiVDAC1hi T cells in the PBMC of the COVID-A patients.  
For example, as described earlier, the H3K27me3hiVDAC1hi T cells from the 
COVID-A patients demonstrated significantly decreased expression of Glut1, a metabolic 
marker associated with T cell effector function, compared with COVID-R and influenza 
(Figure 3.4G). Notably, the level of Glut1 on the H3K27me3hiVDAC1hi T cells 
corresponded to disease severity in COVID-A patients. While the most severe patients 
(requiring mechanical ventilation) expressed significantly lower levels of Glut1, the 
patients with more mild disease (hospitalized and requiring low or high flow oxygen) 
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demonstrated H3K27me3hiVDAC1hi T cells with Glut1 levels similar to COVID-R patients 
and influenza patients (Figure 3.4G). In contrast, H3K27me3hiVDAC1hi T cells from 
COVID-A patients had significantly increased expression of the mitochondrial protein 
Tomm20 and KLRG1, a marker associated with T cell senescence and age-related 
functional defects (Figure 3.4G)212. Thus, despite similar levels of H3K27Me3 and VDAC1 
expression, the expression of proteins involved in metabolic programming of these cells 
is distinct between severe acute COVID-19 patients and mild/recovered COVID-19 or 
hospitalized influenza patients, all of whom recovered. Therefore, these cells represent 
a population truly unique to acutely ill COVID-19 and may provide insight into the 
immune dysregulation observed in SARS-CoV-2 infection. 
 
3.2.2 Dysfunctional Mitochondria in T cells of Acutely Ill COVID-19 Patients Leads to 
Apoptosis in a VDAC1-Dependent Fashion 
 
In order to elucidate the functional significance of these T cells that were highly 
prevalent in acute COVID-19, single-cell RNA sequencing was performed on six COVID-A 
patients, all of which had more than 50% of the T cells of interest as determined by flow 
cytometry, and three healthy controls. Evaluating gene programs enriched in T cells 
derived from COVID-A patients revealed an upregulation of cell death programs, as has 
been reported previously (Figure 3.5A, red bars)223. Furthermore, these data 
demonstrated evidence of mitochondrial dysfunction, including downregulation of 
several programs associated with mitochondria function, organization, respiratory chain 
complex assembly, oxidative phosphorylation, and electron transport coupled proton 
transport (Figure 3.5A, blue bars).  
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To investigate whether elevated levels of VDAC1 and Tomm20 was indicative of 
altered mitochondrial function in these T cells, we performed electron microscopy on 
PBMC from additional COVID-A patients and healthy controls to examine the 
lymphocyte mitochondria. This analysis revealed markedly dysmorphic, irregularly 
shaped mitochondria with incomplete cristae in lymphocytes from COVID-A patients 
compared to lymphocytes from healthy controls, consistent with dysregulated 
mitochondrial function (Figure 3.5B). In addition to displaying morphological 
characteristics of apoptosis, lymphocytes from COVID-A patients showed prominent 
degenerative changes including large cytoplasmic vacuoles.  
We next performed confocal microscopy of PBMC stained with anti-CD3 and 
MitoTracker Deep Red, which stains mitochondria. CD3+ T cells from COVID-A patients 
demonstrated less distinct mitochondrial staining versus healthy controls (Figure 3.5C), 
consistent with the dysmorphic mitochondria observed by EM. Based on these findings 
and along with the observed decreased mitochondrial programs by RNA-seq and 
presence of apoptotic cell morphologies by EM, we hypothesized that VDAC1 might act 
to facilitate release of mitochondrial cytochrome c to the cytosol, leading to 
apoptosis224,225. We therefore performed immunofluorescence analysis of endogenous 
cytochrome c and found it to be present in the cytoplasm of a subset of CD3+ T cells 
from COVID-A patients, whereas in healthy controls, cytochrome c was localized to the 
mitochondria (Figure 3.5D). Of note, while release of cytochrome c into the cytoplasm 
can lead to rapid cell death, in our procedure, the cells were fixed immediately after 
thawing, prior to measurement of endogenous cytochrome c. Employing this technique 
 70 
enabled us to capture a subset of T cells undergoing active mitochondria-induced 
apoptosis. Interestingly, the presence of H3K27me3hiVDAC1hi T cells was highly 
predictive of the development of lymphopenia during the course of hospitalization. We 
observed a highly significant (p<0.0001) negative correlation between the frequency of 
these cells and the peripheral lymphocyte count as measured after 7 days of 
hospitalization (Figure 3.5E). This highly significant negative correlation supports the 
hypothesis that mitochondrial-induced apoptosis is in part contributing to the 
lymphopenia that develops in the COVID-A patients during the course of their 
disease127,226. Thus, the unique population of T cells found in the COVID-A patients 
display mitochondrial dysfunction consistent with cytochrome c release into the 
cytoplasm and subsequent induction of apoptosis. Given these findings and the fact that 
VDAC1 can facilitate caspase-mediated cell death224,227, we hypothesized that the high 
expression of VDAC1 in the setting of dysmorphic mitochondria was directly linked to 
increased susceptibility to cell death in these T cells.  
To test this hypothesis, we cultured PBMC from COVID-A patients and healthy 
controls for 48 hours in vitro in the presence of media alone, the mTOR inhibitor 
rapamycin, the VDAC1 oligomerization inhibitor VBIT-4218,219, or the global caspase 
inhibitor ZVAD (Figure 3.6A). We observed decreased T cell survival in media alone from 
the PBMC of COVID-A patients when compared to healthy controls, confirming 
increased cell death in COVID-A T cells. Interestingly, survival of the COVID-A T cells was 
rescued with either the VDAC1 oligomerization inhibitor or the pan-caspase inhibitor, 
but not the mTOR inhibitor. These findings are consistent with the fact that VDAC1 
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oligomerization and interaction with BCL2 family proteins is thought to enable pore 
formation within the mitochondrial outer membrane, allowing for cytoplasmic release 
of cytochrome c, which initiates the caspase cascade to induce cellular 
apoptosis224,227,228. Notably, neither VBIT-4 nor ZVAD enhanced survival of the healthy T 
cells, demonstrating that this mechanism of cell death contributes to loss of viability in 
the COVID-A T cells but not in the T cells from the healthy controls. Interestingly, the 
COVID-A T cells treated with ZVAD and VBIT-4 treatment demonstrated robust response 
to anti-CD3 + anti-CD28 stimulation, similar to the healthy T cells, indicating the ability 
to functionally rescue the T cells (Figure 3.6B). These data, combined with the 
observations of increased cytoplasmic cytochrome c suggest that VDAC1 is promoting 
cell death through direct pore formation (Figure 3.6C). However, these observations do 
not rule out a role for an interaction between VDAC1 and BAX/BAK to promote cell 
death in these T cells.  
In light of the propensity of the T cells from the COVID-A patients to undergo 
apoptosis, we wanted to verify that our results did not reflect differences in cell survival 
after freezing. When we compared fresh and frozen PBMC from four COVID-A patients, 
we observed an increased frequency of the H3K27me3hiVDAC1hi T cells in the freshly 
stained PBMC (Figure 3.6D) compared to those frozen and thawed. Thus, our studies are 




3.3 B cell Frequencies and Phenotypes Differ in the Memory 
Compartment in COVID-19 
 
Using our assay, we also interrogated the metabolic programs of B cells and NK cells. In 
contrast to T lymphocytes, we did not observe marked differences in the frequencies of 
naïve B cells between any viral infections and the healthy controls (Figure 3.7). 
Consistent with recent reports, we did observe an increase in the peripheral antibody-
secreting cells (ASC) in the COVID-A patients226. All of the viral infections were 
associated with a significant increase in the memory B cells versus healthy controls, 
while only the COVID-A and hepatitis C patient groups demonstrated an increase in the 
activated memory B cells. The COVID-A and influenza patient groups both had a higher 
percent of atypical memory B cells compared to PBMC from the hepatitis C and the 
COVID-R patient groups. Overall, global UMAP projection demonstrated only subtle 
phenotypic differences among the different groups in the B cell compartment.  
 
3.4 Unique NK Cell Population in COVID-A Subjects Identified by High 
Dimensional Phenotyping Analysis  
 
When we examined the NK cells, we found no significant differences in frequency when 
comparing the COVID-A patients, the COVID-R patients and the influenza patients 
(Figure 3.8). Conversely, HD flow analysis revealed a population of CD56+ NK cells in the 
COVID-A patients not present in the influenza patients or in the healthy controls. This 
population was defined by the upregulation of classical activation markers CD69, Ki67, 
and CD49a and by increased expression of the metabolic markers Tomm20, CPT1a, and 
HKII. When we compared NK cells from COVID-A patients with COVID-R patients, we 
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observed differences in CD56+ and CD56bright cells driven mainly by differential 
expression of markers of activation. While the precise significance of these cells is 
unclear, their generation can potentially provide important clues into the dysregulated 
systemic inflammation characteristic of acutely ill COVID-A patients. 
 
3.5 Expansion of Neutrophils and PMN-MDSCs in Acute COVID-19 
Next, we examined myeloid cells in the PBMC of the COVID-A patients employing our 
HD immunometabolic assay (Figure 3.9). Consistent with prior reports, acute COVID-19 
was associated with a decreased percentage of myeloid dendritic cells (mDC) and 
plasmacytoid dendritic cells (pDC) in PBMC and limited differences in monocyte 
populations226,229 (Figure 3.9A-C). Although cryopreservation is known to affect the 
recovery of myeloid populations, a rapid protocol to stain cells immediately post thaw 
was utilized to minimize this effect and allowed for recovery of monocytic and 
granulocytic cells post-cryopreservation, when compared to freshly isolated cells (Figure 
3.9F-G).  
Visualization of myeloid cells by UMAP projection revealed two distinct 
populations, which once again only became apparent upon interrogating metabolism 
(Figure 3.10A-B). We first identified CD15+ granulocytic cells in COVID-A patients, which 
were entirely absent from the healthy controls (Figure 3.10A-B). Evaluating the 
granulocytic cells further revealed a combination of low-density neutrophils, basophils, 
and polymorphonuclear (PMN)-myeloid derived suppressor cells (MDSC) (Figure 3.10C, 
Figure 3.9). Increased neutrophil counts have been previously observed in COVID-19 
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patients226,229 and low-density neutrophils can be found in the PBMC fraction during 
inflammation, representing both immature neutrophils and activated/degranulated 
neutrophils230. Immunosuppressive PMN-MDSC are often associated with chronic 
inflammation, as is seen in cancer, obesity and chronic viral infection231. Although low 
levels of PMN-MDSC were detectable in chronic hepatitis C, there were significantly 
more in COVID-A patients (Figure 3.10C). Of note, the PMN-MDSC expressed the highest 
levels of VDAC1 within the PBMCs, higher than the H3K27Me3hiVDAC1hi pre-apoptotic T 
cells (Figure 3.10D). However, in contrast to the VDAC1+ T cells, the PMN-MDSC had 
concurrent upregulation of HKII, which is known to associate with VDAC1 and prevent 
apoptosis232. Thus, the granulocytic suppressor cells (PMN-MDSC) in the PBMC of the 
COVID-A patients possessed a unique metabolic signature (Figure 3.10E). The expression 
of VDAC1 and HKII provide further information into the metabolic programing of these 
cells and may provide potential therapeutic targets for an immunosuppressive MDSC 
compartment. 
 
3.6 Metabolically Distinct Myeloid Cells in COVID-A with Differential HLA-
DR Expression 
 
We next identified a population of monocytic cells present in COVID-A patients that 
expressed high levels of carnitine palmitoyltransferase 1a (CPT1a), an enzyme found 
within the mitochondrial membrane that is essential for fatty acid oxidation. 
Additionally, these myeloid cells also expressed high levels of VDAC1 (Figure 3.11A-B). 
Interestingly, CPT1a has been associated with both inflammasome activation and ROS 
production233,234, and a potential role for inflammasome activation in contributing to the 
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pathogenesis of SARS-CoV-2 infection has been noted by others235. When comparing the 
myeloid cells found in COVID-A versus COVID-R patients, there was a similar metabolic 
program driven by high expression of CPT1a and VDAC1, however, there was differential 
expression of HLA-DR (Figure 3.11C). During acute infection, a large portion of the 
CPT1a+VDAC1+ myeloid cells were HLA-DR-, and thus classified as monocytic MDSC236 
(M-MDSC) (Figure 3.11C). A decrease in HLA-DR expression on myeloid cells during 
COVID-19 infection has been previously noted by other groups as well128,235,237. M-MDSC 
are known potent suppressors of T cell responses, and in line with this role of 
immunosuppression, they expressed diminished levels of costimulatory molecules such 
as CD86 compared to their HLA-DR+ counterparts (Figure 3.11D). Further, they 
expressed elevated levels of CCR2, indicating recent migration out of the bone marrow 
(Figure 3.11D).  
Conversely, the HLA-DR+ component, composed of both CD14+ and CD16+ 
monocytes, was elevated during active infection, and remained high during recovery 
(Figure 3.11C). HLA-DR+ monocytes are capable of producing robust amounts of 
cytokines and also providing antigen presentation and T cell costimulation, as indicated 
by the elevated CD86 expression (Figure 3.11D). The differential expression patterns of 
these monocytic populations between the infected and recovered patients may 
represent a shift from immunosuppressive (DR-, MDSC) to a productive immune 
response (DR+, stimulatory monocytes).  
To better understand the function of the two subsets of CPT1a+VDAC1+ HLA-DR-/+ 
cells, we assessed single-cell RNA sequencing data from the PBMC of three COVID-A 
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patients that had high levels of the CPT1a+VDAC1+ myeloid cells, as determined by flow 
cytometry (Figure 3.11E). The analysis revealed four distinct clusters (Figure 3.11E). 
Clusters 1 and 3 both had elevated levels of VDAC1 and CPT1a, but cluster 1 expressed 
relatively lower levels of HLA-DR compared to cluster 3 (Figure 3.11E), corresponding to 
the two populations of cells identified by flow cytometry. Cluster 3 (HLA-DR+) exhibited 
gene programs associated with a productive immune response, such as antigen 
processing/presentation and a type I IFN response (Figure 3.11F). In contrast, cluster 1, 
which demonstrated decreased HLA-DR expression and contained the cells that were 
more abundant in acute infection, expressed gene programs associated with reactive 
oxygen species (ROS) production, exocytosis and targeting proteins to the membrane 
surface (Figure 3.11F). Therefore, the gene programs supported the hypothesis of an 
increased immunosuppressive myeloid compartment during acute infection, which 
transitions into an immunostimulatory profile during resolution. Specifically, the HLA-
DR- cluster expressed high levels of genes for secreted alarmins such as S100A9 and 
S100A8 and chemokines such as CXCL2 and CXCL3238 (Figure 3.11G). Overall, our data 
demonstrate that the immune activating DR+ cells are present in both the COVID-A and 
COVID-R patients (Figure 3.11H). However, the DR- M-MDSC suppressor cells are found 
in the COVID-A patients but not the recovered COVID patients (Figure 3.11I).  
The dichotomy based on HLA-DR expression of these metabolically unique cells 
and association with productive or inhibitory immune responses prompted us to 
examine the relationship between the HLA-DR+ and HLA-DR- CPT1a+VDAC1+ myeloid 
cells and disease severity. The CPT1a+VDAC1+ HLA-DR- cells represent less than 0.5% of 
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total PBMCS of COVID-R patients, however, the percentage of these cells is significantly 
higher in COVID-A patients requiring mechanical ventilation (on average 3.5% of PBMCs) 
than in COVID-A patients with less severe disease (0.7% of PBMCS) (Figure 3.11J). While 
we do not observe these cells in the (non-respiratory) hepatitis C infected patients, the 
DR- cells are present in the influenza patients (Figure 3.11I,J). However, the overall 
percentage of these cells in the influenza patients is significantly lower than that of the 
severe COVID-A patients. All influenza patients recovered and this finding is consistent 
with the fact that although these patients have been hospitalized, they are more in line 
with the mild COVID-A patients and overall, far less ill than the severe COVID-A patients. 
 
3.7 The Unique T cell and Myeloid Subsets in PBMC of Acutely Ill COVID-
19 Patients Distinguishes Disease Severity 
 
Finally, while our immune-metabolic approach has defined previously undescribed T cell 
and myeloid subsets in the COVID-A patients that provide insight into the mechanism of 
immune dysfunction and pathogenesis, we wondered whether the presence of these 
cells could be exploited to predict and track severity of disease. To this end, we used a 
random forest model to identify features most important in distinguishing COVID-19 
patients from healthy controls, influenza, or between disease severity and recovery 
(Figure 3.12). We found that the proportion of H3K27Me3hiVDAC1hi CD4 T cells was 
highly predictive when comparing healthy controls to COVID-19 (Figure 3.12A). 
Alternatively, when distinguishing between disease severity or between an otherwise 
similar respiratory viral disease, the innate compartment was highly informative (Figure 
3.12B-C). As previously described, the absence of pDCs was able to distinguish mild from 
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severe COVID-19 (Figure 3.12C). However, we also found that the HKII+ PMN-MDSC cells 
we identified were associated with severe disease and could readily discriminate severe 
COVID from influenza, recovered and healthy controls (Figure 3.12A-B,D). In addition, 
CPT1a+VDAC1+ myeloid cells (particularly the presence of HLA-DR- M-MDSCs) were 
associated with more severe disease (Figure 3.12C). Finally, as prior publications have 
shown the association between COVID-19 severity and age, sex, and BMI, we further 
added these variables to our COVID-19 severity analysis127 (Figure 3.12E). The feature 
importance analysis confirmed that in our data set sex and BMI are among the most 
important features in predicting COVID-19 severity. Interestingly, they were less 
predictive than the percentage of VDAC1+CPT1a+ myeloid cells, pDC, and 
H3K27Me3hiVDAC1hi CD4+ cells (Figure 3.12E). Adding the percentage of VDAC1+CPT1a+ 
myeloid cells, pDC, and H3K27Me3hiVDAC1hi CD4+ improved prediction of COVID-19 
severity compared to basic clinical information (Figure 3.12F), highlighting the important 
contribution of the immune cell populations identified to disease severity. This model 
was validated using an additional 18 COVID-A patients and 5 COVID-R patients not 
studied in the original cohort (Figure 3.12G). 
 
3.8 Perspectives and Future Directions 
 
Considering that metabolic reprogramming plays an integral role in immune cell 
differentiation and function, we devised an assay to interrogate metabolic programs at a 
single cell level. Previous studies examining PBMC from COVID-19 patients have 
revealed generalized changes in cellular subsets and cytokines consistent with increased 
inflammation127,128,226,229. In contrast, by employing our approach we were will able to 
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identify robust, distinct T cell and myeloid subsets that were unique to the PBMC of the 
COVID-A patients. These previously undescribed populations of cells provide important 
insight into the immune dysfunction and pathogenesis of SARS-CoV-2 infection. 
Furthermore, as well as defining novel immune cell subsets, our approach reveals a new 
line of inquiry to understanding immune responses in general during infection, 
inflammatory diseases, and cancer.  
Institutional safety protocols led to certain experimental limitations of our study. 
For example, mitochondrial studies had to be performed on fixed cells limiting the use 
of certain dyes and limiting our ability to extend the depth of our studies concerning 
mitochondrial dysfunction. Nonetheless, we employed 3 different microscopic 
techniques (Figure 3.5) to prove this point. Along these lines, the fact that the VBIT-4, 
the inhibitor of VDAC1 aggregation, promotes survival in the T cells from the COVID-19 
patients but not healthy controls supports a role for VDAC1 in promoting cell death. 
While we also observe cytochrome c in the cytoplasm of such T cells, we have not 
definitively proven that VDAC1 pore formation leading to cytochrome c in the cytoplasm 
is the definitive/sole mechanism of cell death. Additionally, while our study is 
highlighted by insightful comparisons between SARS-CoV-2 infected patients and 
hospitalized influenza infected patients, limited availability of cells from the influenza 
cohort precluded more in depth functional comparisons between the two sets of 
patients. 
In trying to understand the mechanism of pathogenesis of SARS-CoV-2 infection, 
there has been much focus on over exuberant immune responses and cytokine 
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storm226,235,239. In contrast, our data has revealed the presence of cells consistent with 
dysfunctional and suppressive immune responses. T cells play a critical role in both 
killing virally infected cells and providing help for effective and prolonged anti-viral 
antibody production240. Our data reveals the presence of populations of 
H3K27me3hiVDAC1hi T cells in the COVID-A patients. These cells expressed low levels of 
Glut1, the glucose transporter necessary to support glycolysis during effector responses. 
While increased VDAC1 levels in and of themselves might simply represent increased 
mitochondrial mass, we observed parameters indicative of mitochondrial dysfunction 
and apoptosis signaling in these cells, including altered mitochondrial ultrastructure and 
release of mitochondrial cytochrome c into the cytosol. Furthermore, observed loss of 
cell viability was reversed by treatment with the pan-caspase inhibitor Z-VAD, 
suggesting caspase dependent apoptosis. Rescue from cell death was likewise achieved 
by inhibiting VDAC1 oligomerization, further supporting a mitochondrial mediated cell 
death program. VDAC1 is the most prevalent protein in the mitochondrial outer 
membrane, and acts as the main transporter of nucleotides and metabolites across the 
mitochondrial membrane241. By interacting with pro-apoptotic BCL2 family members, 
VDAC1 oligomerization may allow for pores large enough for release of cytochrome c 
into the cytoplasm224. In addition, VDAC1 has also been shown to facilitate BAX/BAK 
mediated cell death242–244.  
The prevalence of the H3K27me3hiVDAC1hi T cells increased with age and such 
cells were observed in all of the patients over 70 years of age in our study. Interestingly, 
increased age is a known risk factor for severe COVID-19 and aging is associated with a 
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decline in lymphocyte mitochondrial fitness and activity245,246. Additionally, increased 
prevalence of the H3K27me3hiVDAC1hi T cells correlated with lymphopenia in the COVID-
A patients. Lymphopenia has previously been described as a prominent feature of 
COVID-19 and our data suggest that mechanistically this may be due in part to 
mitochondrial-induced cell death124. To this end, our data support direct T cell death, as 
opposed to trafficking to inflamed organs such as the lung247. Further, this dysregulated 
T cell immunity could contribute to a lack of or waning protective immunity or impair 
the functionality of pre-existing cross-reactive T cell immunity248,249. Alternatively, it is 
possible that increased cell death of T cells is driving some of the dysregulated 
inflammation and autoimmune-like features characteristic of COVID-19. Finally, our data 
suggest that therapeutically targeting mitochondrial (metabolic) dysfunction might 
represent a successful strategy for abrogating disease. 
The precise inflammatory mediators leading to the generation of the 
H3K27me3hiVDAC1hi T cells has yet to be determined. Several lines of evidence indicate 
that this T cell phenotype is driven by more than the cytokine environment or TCR 
stimulation alone. Memory T cell subsets are more responsive to secondary cytokine 
signaling compared to naïve T cells250, however, elevated VDAC1 and H3K27me3 
expression was found equally in the naïve and memory compartment. Further, there 
was no expansion of specific TCR clones within the H3K27me3hiVDAC1hi phenotype, 
indicating this is likely not driven by recent antigen-exposure. Because most of the 
hospitalized COVID-A patients were hypoxic, requiring supplemental oxygen, an 
interesting possibility is that SARS-CoV-2-induced inflammation in the setting of hypoxia 
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contributes to the generation of these dysfunctional T cells. Indeed, oxidative 
phosphorylation is required for maintenance of T cell function and is the predominant 
metabolic pathway utilized by resting T cells251. Thus, COVID-19 hypoxia combined with 
a specific inflammatory environment may lead to this metabolically dysregulated T cell 
phenotype. 
Previous studies have demonstrated increased inflammation and activation of 
myeloid cells in COVID-19 patients226,235,237. However, it still remains unclear which of 
these responses are protective and which are pathogenic. Our identification of unique 
myeloid populations in the COVID-A patients shed light on the role of these cells. HKII+ 
VDAC1+ PMN-MDSC were exclusively upregulated in the COVID-A patients, suggesting 
that this population of cells is either contributing to pathogenesis or the consequence of 
dysregulated inflammatory responses. On the other hand, CPT1a+VDAC1+DR+ monocytic 
cells were found in both the acute and recovered patients. DR+ monocytes have 
previously been shown to be associated with productive immune responses in other 
respiratory viral infections252 and single-cell RNA sequencing analysis revealed increased 
antigen processing/presentation and type I IFN responses in such cells. In contrast, the 
CPT1a+VDAC1+DR- M-MDSC were found exclusively in the COVID-A patients and further, 
the frequency of these cells was positively correlated with severity of disease. As such, 
the presence of these suppressor cells seems to be indicative of dysregulated 
inflammation. Finally, CPT1a has been associated with inflammasome activation, which 
has been observed in COVID-19 patients, and its role in fatty acid oxidation supports 
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modulators of either fatty acid oxidation or inflammasome signaling as potentially novel 
therapeutic targets to mitigate disease. 
Finally, the unique cellular subsets described herein represent potentially potent 
biomarkers to predict and track severity of disease. The importance of the described cell 
populations is highlighted by their ability to robustly contribute to distinguishing severe 
and mild COVID-19 and acute COVID-19 from other viral infections. Consequently, 
tracking these unique cells might identify those at highest risk of disease progression 
and provide important criteria for enrollment into clinical trials as well as provide a 
surrogate marker for tracking efficacy of new potential treatments. Together, our data 
demonstrate the utility of broad immuno-metabolic phenotyping to identify subsets of 
immune cells that have the potential to not only provide insight into disease 
pathogenesis and predict severity of disease but also, importantly, to define novel 
metabolic targets for treatment.  
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Male N (%) 19 (50) 
Female N (%) 19 (50) 
Mean age (range) 59.7 (20-82) 
Mean BMI (range)  32.2 (17.5-51.2) 
Current smoker N (%) 
 
  0 (0) 
Race and Ethnicity  
Race                                          N (%) 
Black 17 (47.5) 
White 11 (28.9) 
Other*   7 (18.4) 




  N (%) 




Maximum Disease Severity**   N (%)                                                   
MinO2  14 (36.7) 
HFO2    4 (10.5) 
Ventilated Lived  15 (39.5) 




  N (%) 
Hypertension  21 (55.3) 
Diabetes mellitus 15 (39.5) 
COPD/asthma 12 (25.0) 
Coronary artery disease   2 (5.2) 
HIV infection   3 (7.9) 
 
*Most self-identified as Hispanic/Latinx. 
**Maximum disease severity indicates the most severe COVID-19 disease class for the 
patient while under observation: MinO2= no or low flow oxygen required, HFO2= high 
flow oxygen required, Ventilated= patient required intubation and survived, Died = 
patient died (ventilated or not) 
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Male N (%) 19 (50) 9 (43) 6 (60) 2 (33) 7 (70) 
Female N (%) 19 (50) 12 (57) 4 (40) 4 (67) 3 (30) 




Figure 3.1. Gating strategies for COVID-19 flow cytometry panels. 
 
Representative flow plots from an acute COVID-19 subject show gating of all peripheral immune 
cell subsets assessed by one of two immuno-metabolic panels (A) T cell panel or (B) Myeloid and 




H3K27me3 Histone Methylation 
CPT1a Fatty Acid Oxidation 
GLUT1 Glycolysis 








Figure 3.2. Frequencies of T cell subsets and activation markers reveal few COVID-19 
specific differences. 
 
A. Frequency of indicated cell subset as percent of total live cells. Each dot represents one 
individual, significance tested using unpaired Kruskal-Wallis test compared to healthy control. B. 
CD4:CD8 ratio. Each dot represents one individual, significance tested using unpaired Kruskal-
Wallis test compared to healthy control. C. Frequency of CD4+ and D. CD8+ T cell subsets shown 
as percent of CD4 or CD8, respectively. Each dot represents one individual, significance tested 
using unpaired Kruskal-Wallis test compared to healthy control. E-G. UMAP projection of MFI 
heatmap overlays of indicated proteins. Significance is indicated as compared to healthy control, 
































































































































































































































































Figure 3.3. Identification of novel metabolically distinct T cells in COVID-19 patients. 
 
A. Concatenated flow cytometry data depicted as UMAP projection of CD3+ T cells from healthy 
control (HC, grey) and hospitalized acute COVID-19 patients (COVID-A, blue). The two markers 
discovered to drive segregation of the COVID-A and HC cluster, H3K27Me3 and VDAC1, are 
depicted as histogram overlays and MFI heatmap overlays on UMAP projection.  B. 
Representative flow plots of H3K27Me3+VDAC1+ T cells. C. Healthy PBMCs were stimulated for 24 
hours with anti-CD3 and anti-CD28 and evaluated for metabolic enzymes using flow 
cytometry.  Representative histograms of unstimulated (grey) and stimulated (purple) cultures. 
D. Histograms comparing H3K27Me3+VDAC1+ T cells (pink) and remaining T cells (blue) from 
concatenated pooled COVID-A donors for indicated proteins. E. TCR Simpson Clonality from 
sorted H3K27Me3+VDAC1+ T cells (pink) and remaining T cells (blue). F. Frequency of 
H3K27Me3+VDAC1+ as percent of CD4 or CD8 T cells.  Each dot represents one patient sample, 
significance tested using unpaired Mann-Whitney test.  G. Frequency of H3K27Me3+VDAC1+ as 
percent of CD4 (black) or CD8 (grey) stratified by age of COVID-A patients.  
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Figure 3.4. Novel H3K27me3hiVDAC1hi T cells are unique in COVID-19 compared with 
other viral infections. 
 
A. UMAP projection of pooled donors with active infection, color coded by disease. B. UMAP 
projection of acute and recovered COVID-19 compared to healthy controls. C. UMAP projection 
of influenza and acute COVID-19 compared to healthy controls. D. Frequency of 
H3K27Me3+VDAC1+ CD4 and CD8 T cells as percent of total live cells. E. Representative gating of 
H3K27Me3+VDAC1+ CD4 T cells from multiple disease states. F. Hierarchical clustering of 
H3K27Me3+VDAC1+ CD4 T cells based on expression (MFI values) of indicated 
proteins.  Comparison of hospitalized acute COVID-19 infection (dark blue), recovered COVID-19 
(light blue) and hospitalized influenza (red).  G. Normalized MFI of GLUT1, TOMM20 and KLRG1 
on H3K27Me3+VDAC1+ CD4 T cells in all patients where H3K27Me3+VDAC+ T cells compromise 
greater than 10% of total CD4 population and representative histogram overlays of MFI. Each dot 
represents one patient sample, significance tested using unpaired Kruskal-Wallis test compared 






Figure 3.5. T cells from COVID-19 subjects demonstrate parameters of mitochondrial 
dysfunction and apoptosis signaling, correlating with development of lymphopenia. 
 
A. Single-cell RNA sequencing analysis of 6 COVID-19 subjects and 3 HC were evaluated for CD3+ 
T cells. Genes distinguishing T cells from COVID-19 patients compared to HC were evaluated for 
statistical over representation using GO biological processes as gene sets and categorized into 
higher level annotation using ReviGO.  Displayed is the enrichment score for each gene set and 
color corresponds to programs in upregulated genes (red) and downregulated genes (blue). B. 
Representative electron microscopy images of PBMCs from a COVID-A patient and a healthy 
control. C. Representative confocal images of PBMCs from a COVID-A patient and healthy control 
with mitochondria labeled using MitoTracker Deep Red (pink), CD3+ T cells labeled (green) and 
nuclei labeled with DAPI (blue). D. Representative fluorescence images of PBMCs from 3 COVID-
A subjects and one healthy control (left) immunostained for cytochrome c (green) and CD3 (red), 
and nuclei labeled with DAPI (blue). Plot profiles of intracellular cytochrome c fluorescence 
intensity distribution (right).  E. Correlation of lymphocyte count with frequency of 
H3K27Me3+VDAC1+ out of total CD4+ T cells from day 0-6 (left) or day 7-14 (right) of study 
enrollment, including all symptomatic patients. Each dot represents one subject and color 
corresponds to days since onset of lymphopenia (black = no COVID-19 related lymphopenia 







Figure 3.6. Loss of T cell survival can be rescued by targeting VDAC1 or caspases. 
 
A. PBMCs from acute COVID-19 patients or healthy controls were cultured for 48 hours in media, 
rapamycin (100nM), VBIT-4 (300nM), or ZVAD (60nM).  T cell survival was calculated as the 
percent CD4 or CD8 T cells remaining from initial plating.  Significance tested using two-way 
ANOVA with each drug compared to the media control, n=9. B. T cells were stimulated with anti-
CD3/CD28 (purple) for 48 hours and surviving T cells from COVID-19 patients are able to respond 
by upregulating HLA-DR, CD69, CD25 and GLUT1 to the same extent as healthy controls compared 
to unstimulated controls (grey). C. Graphical depiction of proposed mechanism of mitochondrial 
cell death signaling in COVID-19 T cells. D. Representative plots show increased H3K27me3+VDAC+ 
CD4+ T cells in a COVID-A subject with cells stained fresh compared to after cryopreservation. *p 
< 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.  
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Figure 3.7. B cell frequencies and phenotypes differ in the memory compartment in 
COVID-19. 
 
A-D. Frequency of indicated cell subset as percent of total live cells. Each dot represents one 
individual, significance tested using unpaired Kruskal-Wallis test compared to healthy control. (E-
F) UMAP projection performed on a subset of COVID-A (blue), hospitalized Flu (red) and HC 
subjects (grey) (E) or COVID-A (blue) and COVID-R (light blue) (F). Manual gating overlays on UMAP 
projection color code total B cell (top) and memory B cell (bottom) subsets. UMAP projection MFI 
heat maps of indicated proteins. Significance is indicated as compared to healthy control, *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, if no significance is indicated the test is non-significant. 
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Figure 3.8. Unique NK cell population in COVID-A subjects identified by high-
dimensional phenotyping analysis. 
 
A. Frequency of indicated cell subset as percent of total live cells. Each dot represents one 
individual, significance tested using unpaired Kruskal-Wallis test compared to healthy control. B. 
UMAP projection of total NK cells performed on a subset of COVID-A (blue), hospitalized Flu (red) 
and HC subjects (grey) (left). Arrow indicates unique COVID-A specific cluster identified. Manual 
gating overlays on UMAP projection (top) color code CD56+ (purple) and CD56 bright (pink) cells. 
UMAP projection MFI heat maps of indicated proteins are shown right. C. Similar analysis as in (B) 
was performed on a subset of COVID-A (blue) compared to COVID-R (light blue) subjects. 
Significance is indicated as compared to healthy control, *p<0.05, **p<0.01, ***p<0.001, 
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Figure 3.9. Myeloid subsets in viral infections. 
 
A-C. Frequency of indicated cell subset as percent of total live cells. Each dot represents one 
individual, significance tested using unpaired Kruskal-Wallis test compared to healthy control. D. 
Frequency of indicated cell subset as percent of total live cells. To assess how dendritic cell 
frequencies changed in recovery, significance was tested using unpaired Kruskal-Wallis test 
comparing all possible combinations. E. UMAP projection of total myeloid cells performed on a 
subset of hospitalized Flu (red) and HC subjects (grey). Manual gating overlays on UMAP 
projection color code myeloid and B cell subsets in the UMAP space. MFI histogram overlays of 
CD14+ myeloid populations of indicated proteins for hospitalized Flu (red) and HC (grey). 
Significance is indicated as compared to healthy control (A-C), or between groups (D).  F. 
Frequency of indicated cell subset as percent of total live cells when sample was processed fresh 
or after cryopreservation (frozen). Each dot represents one individual. Significance tested using 
Wilcoxon matched-pairs signed rank test. G. Principal component analysis of frequencies of innate 
cell subsets show differences driven by patient variability and not cryopreservation. *p<0.05, 















































































































































































































































































































Figure 3.10. Metabolically distinct granulocytic immunosuppressive myeloid derived 
suppressor cells in PBMC of COVID-19 patients. 
 
A. Concatenated flow cytometry data depicted as UMAP projection of CD3-CD19-CD56- myeloid 
cells from healthy control (HC, grey) and acute COVID-19 patients (COVID-A, blue). B. UMAP 
projection of MFI heatmap overlays of indicated proteins. C. Representative gating of CD15+ 
granulocytic subsets basophils, eosinophils, neutrophils and PMN-MDSC across all disease states 
studied. D. Flow plot comparing HKII and VDAC1 expression in HC T cells (grey), COVID-A T cells 
(dark blue) and COVID-A PMN-MDSC (light blue). E. Frequency of indicated cell subset as percent 
of total live cells. Each dot represents one patient sample, significance tested using unpaired 
Kruskal-Wallis test compared to healthy control. *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 
0.0001    
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Figure 3.11. Identification of metabolically distinct monocytic myeloid derived 
suppressor cells in PBMC of COVID-19 patients track with disease severity. 
 
A. Concatenated flow cytometry data depicted as UMAP projection of CD3-CD19-CD56- myeloid 
cells from healthy control (HC, grey) and acute COVID-19 patients (COVID-A, blue). B. Histogram 
overlays of MFI for metabolic markers CPT1a and VDAC1 from HC (grey) or COVID-A patients 
(blue). C. Representative gating of CPT1a+VDAC1+ myeloid cells (gated on CD3-CD19-CD56- and 
CD33+) and subset of CPT1a+VDAC1+ cells based on HLA-DR expression. D. Histogram overlays of 
MFI for indicated proteins from CPT1a+VDAC1+HLA-DR+ (red) or CPT1a+VDAC1+HLA-DR- 
(orange) cells. E. UMAP projection of scRNA seq of myeloid cells from three COVID patients with 
detectable CPT1a+VDAC1+ myeloid cells by flow cytometry colored by identified clusters 0-3. 
Expression of indicated genes within cluster 0-3. Each dot represents a single cell. F. Genes 
identifying cluster 1 (CPT1a+VDAC1+ HLA-DRdim) and cluster 3 (CPT1a+VDAC1+ HLA-DRhigh) were 
evaluated for statistical over representation using GO biological processes as gene sets and 
categorized into higher level annotation using ReviGO.  Heatmap color corresponds to the 
enrichment score in upregulated genes (red) and downregulated genes (blue), x indicates a non-
significant enrichment. G. Expression of indicated gene within cluster 0-3. Each dot represents a 
single cell. H-I. Frequency of HLA-DR- CPT1a+VDAC1+ myeloid cells and HLA-DR+ CPT1a+VDAC1+ 
myeloid cells as percent of total live cells. Each dot represents one individual, significance tested 
using unpaired Kruskal-Wallis test compared to healthy control. J. Frequency of CPT1a+VDAC1+ 
DR+/- cells in COVID-A patients were stratified by disease severity (Severe= deceased or required 
mechanical ventilation, Mild= hospitalized with low or high flow oxygen).  Each dot represents 
one patient sample, significance tested using two-way ANOVA comparing either HLA-DR+ vs HLA-
DR- within each category or HLA-DR+ or HLA-DR- across each category. *p < 0.05, **p < 0.01, ***p 




Figure 3.12. Presence of immune cells with distinct metabolic profiles predicts disease 
severity. 
 
A-D. Feature importance of distinguishing COVID-A patients and healthy controls, COVID-A 
patients and Flu patients, severe COVID-A patients and COVID-R patients, or severe COVID-A 
patients and mild COVID-A patients as indicated. Each feature is depicted as a frequency of total 
live cells, unless otherwise indicated in the case of proportion of cell subset with a specific 
metabolic phenotype. E. Feature importance analysis after adding basic clinical information (i.e., 
age, sex, and BMI) to the RF model for classifying severe vs. mild COVID-A. F. ROC curves for 
comparing the performance of prediction models trained using the top-five-ranked features (i.e., 
top5) and basic clinical information (i.e., baseline) for classifying severe vs. mild COVID-A. AUC is 
indicated. G. The data were confirmed using a validation cohort including 5 COVID-R, 10 severe 
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